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ABSTRACT
The total enantioselective and formal racemic syntheses of malbrancheamide B, 
a bicyclo[2.2.2]diazaoctane-containing fungal metabolite are described. Over 
seventy distinct [2.2.2]diazabicycles have been isolated from fungal sources 
spanning three genii. This class of molecules displays remarkable structural 
diversity and many members have demonstrated biological activity. Key to the 
successful syntheses of malbrancheamide B was a novel domino reaction 
sequence involving a 1-pot aldol condensation, alkene isomerization, and [4+2] 
cycloaddition. In the case of the enantioselective synthesis, a chiral, nonracemic 
aminal auxiliary on the diketopiperazine diene-precursor was used to direct facial 
selectivity in Diels-Alder reaction.
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CHAPTER I
The BICYCLO[2.2.2]DIAZAOCTANE INDOLE ALKALOIDS
Introduction:
A number of prenylated indole alkaloids contain bicyclo[2.2.2]diazaoctane ring systems 
at their core (Figure 1.1).1 This structural motif was originally identified in the brevianamides in 
19692 and isolation of similarly bicyclic metabolites from various aquatic and terrestrial species 
of the Aspergillus, Penicillium, and Malbranchea genera continues today. Despite similar 
polycyclic skeletal structures, this family displays impressive structural diversity among its nearly 
80 naturally occurring members (Figure 1.2).3 Genetic evidence and commonalities in core 
structure and fungal source suggest that these metabolites share closely related biosynthetic 
pathways. While a great deal of insight into the biosynthetic relationships of the many 
subfamilies has been gained over the last four decades, many details remain elusive and thus, 
significant interest on the topic still exists. The core bicycle seen in all members of the family 
has also drawn attention from the community of synthetic chemists. Multiple methodologies 
for creating [2.2.2]diazabicycles have been developed and implemented in natural product total 
syntheses. Presented here is a discussion of this family's general structural themes, synopses of 
the isolation, bioactivities, and biosyntheses of each of the known subfamilies, and selected 
total syntheses that highlight the unique methods by which the diazabicyclic core has been
Figure 1.1: Bicyclo[2.2.2]diazaoctane core
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Figure 1.2: Selected members of the brevianamide family
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constructed. Introduction and discussion of the malbrancheamides will be presented in a later 
chapter.
Structural Themes:
This family of metabolites shares some key structural features in addition to the [2.2.2]- 
diazabicycle. Molecules of this family are biosynthetically derived from a two amino acids, 
generally tryptophan and proline, and one or two isoprene units. Despite their common core 
feature and their similar biosynthetic origins, alkaloids of this family demonstrate remarkable 
structural variety. Members sharing the diazabicyclic core can differ in ring size, number, and 
fusion pattern, in oxidation state, substitution patterns, and in the syn- or anti-relationship of 
the diazaoctane bicycle (Figure 1.3). The numerous permutations coming from variations in all 
these criteria help account for the diversity of observed metabolites.
Figure 1.3: Anti- and syn-diastereomers of the diazabicyclic core
a/?f/'-diastereomer syn-diastereomer
The most visible variation among members of the family occurs in their ring systems. 
Nearly all known examples contain 5-member pyrollidine ring attached to the diazabicycle. 
Exceptions to this trend include the marcfortines which are biosynthetically related to pipecolic 
acid and therefore contain the amino-acid's 6-member ring. Other variations in ring size can be 
seen in differences between alkaloids with and without 7-member dioxepin rings in their 
structure. The number of rings in the bicycles' polycyclic systems range from five to seven and 
several ring fusion patterns are observed including spiro-oxindoles and spiro-indoxyls. Another 
major distinction between subfamilies is the oxidation state of the diazabicyclic core. Each
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family of alkaloids exclusively contains either monoketopiperazine cores as in the 
paraherquamides or diketopiperazines as in the brevianamides.
While all members of this alkaloid family contain the geminal dimethyl substitution 
adjacent to the diazaoctane, other ring substitutions can occur. Brevianamides A and B, for 
example, contain the common gem-dimethyl groups and indole oxidation, but no further 
substituents. The most notable case of substitution in this family is seen in the 
malbrancheamides, which are unique in their indole halogenation.
The last noteworthy variable characteristic of this family is the stereochemical 
configuration of the diazabicyclic core (Figure 1.3). The majority of metabolites with this 
diazaoctane bicycle feature the amide bridge syn to the C-19 proton (brevianamide numbering). 
The relatively less common anti-configuration has so far been observed only in a few examples. 
From a synthetic perspective, this feature poses the most interesting challenge. Replicating the 
enantiomeric purity of such an unusual structure necessitates the development of 
stereoselective methodology.
The Brevianamides:
The brevianamide family of alkaloids was first isolated by Birch et al. from Penicillium 
brevicompactum in 1969.2 Four of the six metabolites originally isolated in this study, 
brevianamides A-D, were found to contain the novel bicyclo[2.2.2]diazaoctane core structure. 
Eventually it was found that brevianamides C and D were artifacts of isolation resulting from 
exposure to light, leaving brevianamides A and B as the sole brevianamide natural products 
containing the unique core (Figure 1.2).4 Brevianamide A gained particular interest after it 
demonstrated modest antifeedant and insecticidal effects.5 Over time, P. brevicompactum has
4
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proven the most viable source for consistent isolation of brevianamides A and B, but P. 
vindication has also been established as a source for brevianamide A.6
Structural elucidation revealed that these naturally occurring [2.2.2]diazabicycles consist 
of diastereomeric hexacyclic ring systems. They display very little substitution on their 
polycyclic skeletal structures, lacking the proline or indole ring substituents observed on other 
indole alkaloids of the family. They contain anti-configured bicyclic cores, a conformation that 
has proven rare in the wake of subsequent isolation of numerous syn-configured diazabicycles. 
Additionally, they contain a spiro-indoxyl moiety not observed in any of the other subfamilies of 
alkaloids.
In order to probe the biosynthesis of these new alkaloids, Birch executed a series of 
radiolabeled precursor incorporation studies shortly after the molecules' initial isolation.2,4 This 
work identified tryptophan, proline, and mevalonic acid as the basic precursors of the 
biosynthetic pathway in P. brevicompactum. Additionally, brevianamide F, the diketopiperazine 
product of condensation between tryptophan and proline, also incorporated into brevianamide 
A, suggesting that it was an intermediate along the biosynthetic pathway. These findings 
prompted Birch's proposal for the early biosynthesis of the brevianamides (Scheme 1.1).
Scheme 1.1: Birch's early-stage biosynthesis of brevianamide A
brevianamide Abrevianamide F deoxybrevianamide E
5
Continuing research into the biosynthesis of the brevianamides was conducted by 
Williams and coworkers who conducted incorporation studies with radiolabeled 
deoxybrevianamide E in P. brevicompactum.7 In these studies it was determined that 
deoxybrevianamide E was indeed a brevianamide A precursor, but that the [2.2.2]cycloadduct 1 
was not. These observations led to the proposal that the [2.2.2]diazabicycle must not form until 
after indole oxidation and pinacol shift, a conclusion that led to alternative biosynthetic pathway 
proposals (Scheme 1.2). Synthetic obstacles have prevented the verification of any part of these 
pathways at this time.
Scheme 1.2: Williams' alternative biosynthetic pathway proposals
^  [ox} 
vl_j pinacol ^[ox] HQR-selective 
indole oxidase
deoxybrevianamide E
1. [ox]
2. IMDA
3. pinacol
Diels-Alder
NH H N ^ i Z /
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[ox]
enolizatioin
NH N
cycloadduct 1 brevianamide A
The Marcfortines:
Eleven years after the original isolation of the brevianamides, Polonsky et al. introduced 
the next three [2.2.2]diazabicycles to the family of alkaloids, marcfortines A, B, and C (Figure
1.4).8 The marcfortines were isolated from a fungus used in the production of blue cheeses
6
which was then called Penicillium roqueforti. Later this fungal species was reclassified and 
subdivided into three distinct species, at which point it was found that only one of these, P. 
paneum, produces the marcfortines.
Figure 1.4: Marcfortines A-C
marcfortine A marcfortine B
marcfortine C
While these metabolites share the family's defining core characteristic, their structural 
features distinguish them from the brevianamides. All three marcfortines contain heptacyclic 
ring systems with syn-configured, monoketopiperazine diazabicycles. Instead of the 
brevianamides' spiro-indoxyl moiety, the marcfortines contain spiro-oxindole skeletal fusion 
patterns with C-6 and C-7 substituted indole rings that connect either dioxepin or pyran 
moieties. The most unusual feature of these molecules is the six-membered, pipecolic acid- 
derived ring rather than the 5-member, proline-derived ring displayed in nearly all other 
[2.2.2]diazabicycles.
While the [2.2.2]diazaoctane bicycles that they share with the brevianamides suggest a 
similar biosynthesis, the distinct structural characteristics, especially that of the pipecolic acid 
ring, separate these alkaloids from those of the other subfamily. Biosynthetic investigation of
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marcfortine A was first carried out by Kuo and coworkers.9 Their work showed, L-tryptophan, L- 
methionine, L-lysine, and acetate as the biosynthetic precursors of the molecule, finding that 
tryptophan incorporated into the spiro-oxindole, methionine contributed via SAM methylation, 
lysine incorporated into the pipecolate, and acetate incorporated into the isoprene units.
The Paraherquamides:
The next major subfamily of [2.2.2]diazaoctane bicycles was discovered upon the
isolation of paraherquamide A from Penicillium paraherquei, also known as P. charlesii, in
1981.10 In the decades following the discovery of paraherquamide A, the paraherquamide
subfamily of alkaloids experienced substantial growth with the discovery and characterization of
some fifteen related molecules. Paraherquamides B-G were discovered next from P. charlesii,
and paraherquamides H and I were found together with a variety of similar metabolites (Figure
1.5) in cultures of either P. cluniae, Penicillium sp. IMI 332995, Aspergillus japonicas, P. charlesii,
or Aspergillus sp. IMI 337664.11 Like brevianamide A, a number of the paraherquamides display
biological activities. Paraherquamides A-G have demonstrated antinematodal properties, but
paraherquamide A remains the most notable for its anthelmintic activity against drug-resistant
parasites.12 Early results indicated that paraherquamide A's anthelmintic effectiveness against
nematodes with broad-spectrum drug resistance could lead to its use as a therapeutic, but it
was subsequently determined that its unacceptable toxicity levels make it unsuitable for such
use.13 Development of semisynthetic paraherquamide derivatives14 has successfully reduced
toxicity in mammals while maintaining effectiveness and has seen some use in combination
treatment in sheep.15
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Figure 1.5: Selected members of the paraherquamide family of alkaloids
OH
Me/..
paraherquamide A 
(VM29919) paraherquamide B
paraherquamide E
Me.
paraherquamide preparaherquamide
Given the number of known paraherquamide metabolites, the structural diversity 
evident in this subfamily of [2.2.2]diazabicycles is not surprising. Features conserved across this 
family include syn-configured [2.2.2]diazabicyclic cores at the monoketopiperazine oxidation 
state similar to those of the marcfortines. Most paraherquamides also possess the same 
tryptophan-derived spiro-oxindole and dioxepin rings seen in marcfortines A and B. Unlike the 
previously discussed family members however, the paraherquamides are distinguished by 
proline-derived rings, moieties upon which many different substitution patterns are observed, 
including several methylation and oxidation patterns.
As with previous subfamilies, biosynthetic interest has revealed the elementary 
components of these molecules. Through a series of feeding experiments with P. cf. canescens, 
the Williams group has found that the synthesis of paraherquamide A in this species
9
incorporates L-isoleucine, 0-methyl-L-proline, L-methionine, and L-tryptophan.16 Further 
feeding studies by this group went on to probe the incorporation of possible intermediates into 
paraherquamide A by P. cf. canescens,17 This study also found that synthetic 
preparaherquamide 19 does incorporate into paraherquamide A, while the diketopiperazine 
analog of preparaherquamide 19 does not. These results suggest that the tryptophan-derived 
carbonyl is reduced to the monoketopiperazine before the [2.2.2]diazabicycle is formed and that 
the key cyclization event must occur before dioxepin or spiro-oxindole formation (Scheme 1.3).
Scheme 1.3: P. cf. canescens incorporation study of preparaherquamide into paraherquamide A
The Stephacidins and Notoamides:
The first metabolite isolated from the next family of diazabicyclic indole alkaloids was
discovered in 1996 by Gloer and White from Aspergillus sclerotlorum (Figure 1.6).“  This
molecule, sclerotiamide A, was originally misclassified as a member of the paraherquamides due
to the skeletal features it shares with that family. It was determined, however, that
sclerotiamide possesses a diketopiperazine core whereas all the paraherquamides contain
monoketopiperazines. Thus, structurally distinct from the monoketopiperazine
paraherquamides, the pipecolic acid-derived marcfortines, and the anti-configured
O
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Figure 1.6: Sclerotiamide, stephacidins A and B, avrainvillamide, and notoamide B
(-)-stephacidin A
HO
sclerotiamide
avrainvillamide
HO
stephacidin B
(+)-notoamide B
brevianamides, sclerotiamide was correctly assessed as the first known member of a new family 
of indole alkaloids. This family saw several major expansions, first in 1999 with the discovery of 
the stephacidins A and B from Aspergillus ochraceus WC76466 by Bristol-Myers Squibb,19 then 
with the isolation of avrainvillamide from Aspergillus sp. CNC358 by Fenical in the same year,20 
and again in 2007 when the Tsukamoto group isolated notoamides A-D from Aspergillus sp. 
MF297-2.21
With the addition of so many novel isolates, there was a corresponding growth in the 
diversity of the family's structural characteristics (Figure 1.6). Sclerotiamide A, the first known 
family member, is structurally defined by its syn-configured core bicyclo[2.2.2]diazaoctane, a 
diketopiperazine core unit, spiro-oxindole and dioxepin rings, an unsubstituted proline ring, and
11
a unique C-10 hydroxyl substitution (paraherquamide numbering). Stephacidin A, B, and 
avrainvillamide in contrast, share these features, but lack the spiro-oxindole and hydroxyl 
substituent.
While the differences in substitution and ring fusion patterns provide interesting points 
of differentiation, it was not until the isolation of stephacidin A, notoamide B, and a novel 
isolate, versicolamide B from new fungal sources, Aspergillus versicolor22 and Aspergillus sp. 
MF297-223 respectively (Figure 1.7), that the subfamily's most interesting feature became 
apparent. Characterization of these metabolites revealed that the stephacidin A and notoamide 
B isolates of A. versicolor were structurally identically to the syn-configured alkaloids previously 
seen and that versicolamide B displayed the comparatively rare anti-configuration which had 
only been previously observed in the brevianamides. These stereochemical conclusions did not, 
however, prove to be true for the isolates of Aspergillus sp. MF29702, which contained 
diazabicyclic rings of the configuration opposite of their A. versicolor-derived analogs. Members 
of this family do exhibit biological activities, although they are generally more moderate than 
the antinematodal properties of the paraherquamides. Sclerotiamide proved to be effective in 
killing Helicoverpa zea corn earworm larvae and inhibiting the growth of surviving larvae.18 
Stephacidins A and B both proved cytotoxic to various human cell culture lines, although it was 
proposed that the activity of the latter was the result of retrodimerization to form 
avrainvillamide in vivo.19 Avrainvillamide was observed to inhibit the growth of multiple- 
antibiotic-resistant strains of Staphylococcus aureus, Steptococcus pyogenes, and Enterococcus 
feccalis21 and was proved cytotoxic to a variety of human cancer cell lines.20 Given the growing 
problem of antibiotic resistance, avrainvillamide and its dimer stephacidin B pose interesting 
candidates for further biological study.
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Figure 1.7: The stephacidin-type alkaloids isolated from specific fungal sources
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Extensive research into the biosynthetic origins of the stephacidin and notoamide family 
of molecules has resulted in a proposal of a comprehensive biosynthesis of stephacidin A and 
notoamide B (Scheme 1.4).24 The proposed biosynthesis of the stephacidin/notoamide family 
begins with a precursor that intersects the early stages of the brevianamide synthesis. The 
common precursor, brevianamide F, undergoes sequential prenylation, oxidation, and 
isomerization until it forms the requisite achiral azadiene precursor of both enantiomeric series 
of natural products. At this point, enantioselective intramolecular hetero-Diels-Alder
13
Scheme 1.4: Proposed biosynthesis of stephacidin A and notoamide B
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establishes the bicyclo[2.2.2]diazaoctane. The absolute conformation of the resulting products 
depend upon the fungal species in question, with either the syn- or anti-conformation created 
exclusively in each organism. The resulting cycloadduct can then undergo oxidative cyclization 
to form stephacidin A, which can in turn undergo oxidative pinacol rearrangement to notoamide 
B.
The Asperparalines:
Asperparaline A was first isolated one year after sclerotiamide by Hayashi and 
coworkers from what was then known as Aspergillus japaconis JV-23.25 This species was later 
divided into seven species, only two of which, A. aculeatinus and A. fijiensis, were shown to be 
produce the diazabicyclic indole alkaloid.26 In a 2000 journal entry, Hayashi et al. reported the 
isolation of asperparalines B and C from the same fungal source that yielded asperparaline A.27 
All of these alkaloids have demonstrated paralytic effects in silkworms and asperparaline A has 
also shown anthelmintic activity against Trichostrongylus colubriformis in gerbils.25,27,28 The 
mechanism of silkworm paralysis by asperparaline A was further investigated by Hayashi et al. 
and was found to involve the molecules effect as a non-competitive antagonist of nicotinic 
acetylcholine receptors in silkworm neurons.29 In a subsequent publication by Everett and 
coworkers, the isolation of asperparaline A and a new asperparaline A-derivative, SB202327 
were reported from Aspergillus fijiensis.11*
Structurally, the four asperparalines are very similar (Figure 1.8). All four asperparalines 
contain syn-configured diazabicycles at the monoketopiperazine oxidation state. They each 
contain 5-member proline-derived rings which may unsubstituted, as in the case of 
asperparaline C, or display either methylation or oxidation. These molecules are distinguished
15
from other [2.2.2]diazaoctane alkaloid families by their 3-spiro-succinimide ring systems. This 
feature is unique to the asperparaline subfamily of alkaloids.
Figure 1.8: The asperparaline family of indole alkaloids
V Me
asperparaline A asperparaline B
V  'Me
O
V Me
asperparaline C O
SB202327
Given the skeletal similarities between the asperparalines and paraherquamides, the 
Williams group was motivated to perform precursor feeding studies aimed at elucidating the 
biosynthetic pathway of asperparaline A.30 These results showed that despite its appearance to 
the contrary, asperparaline A incorporates not only tryptophan, but all the same basic units as 
paraherquamide A. This observation, together with the subsequent detection of 
preparaherquamide in A. aculeatinus, suggest that the biosynthesis of paraherquamide A and 
asperparaline A are unified at least up until preparaherquamide at which point the imide moiety 
of the asperparalines is likely the product of degradation of the paraherquamide indole nucleus 
(Scheme 1.5).111
Chrysogenamide A:
Chrysogenamide A, the only known member of the chrysogenamide family, was first
isolated from Penicillium chrysogenum No. 005 by Zhu and coworkers in 2008 during screening
for molecules with neuroprotective activity.31 Structurally, this alkaloid very closely resembles
16
Scheme 1.5: Proposed unified synthesis of asperparaline A and paraherquamide A
NH.c o 2h
OH
NH
OPP
OH
V 'Me
the marcfortines. It contains an anti-configured [2.2.2]diazabicycle at the monoketopiperazine 
oxidation state, a methylated pipecolic acid ring much like that of the marcfortines, a spiro- 
oxindole ring fusion pattern, and a isoprene substitution at the indole's C-7 position. Little is 
known about the biosynthesis of this compound, while its structural similarities to the 
marcfortines suggest related biosynthesis, the o/it/-configured diazabicycle could indicate a 
distinct pathway.
Figure 1.9: Chrysogenamide A
NH
chrysogenamide A
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Previous Synthetic Methods:
While not every indole alkaloid has been the target of a total synthesis, numerous 
syntheses of select diazabicycles have been completed. From these efforts have emerged five 
distinct methods for establishing the natural products' core structural feature. Syntheses 
representative of each method are presented here as an introduction to these strategies.
Intramolecular SN2' Cyclization:
The first synthetic methodology used to establish the bicyclo[2.2.2]diazaoctane core was 
not performed in the context of a total synthesis until nearly two decades after the original 
isolation of the brevianamides. The Williams group developed an intramolecular SN2' cyclization 
pathway in the synthesis of brevianamide B ( l)32, but later adapted its use for the syntheses of 
several other indole alkaloids.33 The key cyclization event of these syntheses involves a 
diketopiperazine precursor that undergoes enolization and intramolecular nucleophilic attack on 
its allylic halide in an SN2' fashion (Scheme 1.6). This methodology was employed with great 
success in the Williams' brevianamide B synthesis which proved significant in that it represents 
the first synthesis of a diazabicyclic indole alkaloid.
Scheme 1.6: Intramolecular SN2' cyclization
NPMBNPMB
Cl XCI
NPMB
O
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The Williams brevianamide synthesis began with allylated proline derivate 2 (Scheme 
1.7).32 Nucleophilic ring opening of this substrate with p-methoxybenzylamine yielded protected 
amide 3. PMB-protected amide 3 was then converted to diketopiperazine 4 via secondary 
amine acylation and subsequent ring closure. Ozonolysis of 4 resulted in oxidative cleavage of 
the allylic olefin to aldehyde 5. Wittig olefination of 5 followed by sodium borohydride
Scheme 1.7: Synthesis of a SN2' precursor in the Williams synthesis of brevianamide B
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reduction of the resulting a,£-unsaturated aldehyde gave primary alcohol 6. Silyl protection of 
allylic alcohol 6 with TBSCI allowed for diketopiperazine deprotonation and formation of methyl 
ester 7 after quenching with methyl chloroformate. Coupling of the mixture of diastereomers in 
methyl ester 7 with gramine yielded 8. A four step-sequence then removed the methyl ester 
group of 8, converted its silyl-protected primary alcohol to an analogous primary halide, and 
Boc-protected the gramine to give 9. The formation of this allylic halide precursor was crucial to 
the synthesis. The creation of this molecule allowed for the planned intramolecular SN2' 
cyclization event that established the bicyclic core structure of the target alkaloid.
The key intramolecular SN2' cyclization step of the brevianamide B synthesis was first 
attempted with the treatment of precursor 9 with NaH in DMF at room temperature (Table 1.1). 
This reaction gave bicycles 10 and 11 as a 2:1 mixture of diastereomers in 62% combined yield.
Table 1.1: Intramolecular SN2' cyclizations of precursor 9
Cl
NPMB
Boc
ESQ R H
B H h BBfiEBI
i NaH in DMF at rt 2:1 62%
2 NaH in DMF at 100°C 3:97 82%
3 NaH, 18-crown-6 in DMF at rt 4:1 56%
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Interestingly, when the reaction was repeated in benzene at 100°C the epimeric ratio of 10:11 
reversed its preference to 3:97 in 82% combined yield. Desiring an enhanced preference for the 
ont/-configuration characteristic of the target alkaloid, further trials were conducted and it was 
found that exposing 9 to NaH and l8-crown-6 in DMF gives a 4:1 ratio of 10 to 11 in 56% 
combined yield.
Satisfied with the selectivity and yield of the SN2' cyclization for the anti-configured 
diazabicycle, synthetic effort turned to forming the spiro-indoxyl moiety of the targeted 
metabolite. The ont/'-configured [2.2.2]diazabicyclic 10 was exposed to concentrated HCI 
affecting indole deprotection and olefin-cation cyclization (Scheme 1.8). Hexacyclic 12 was then 
converted to the corresponding indoxyl 13 via mCPBA treatment followed by exposure to 
NaOMe. After standard oxidative deprotection strategies failed to remove the PMB-group it 
was found that deprotonation with tBuLi followed by quenching and molecular oxygen 
respectively gave the final product, brevianamide B (1).
Scheme 1.8: Completion of the brevianamide B synthesis
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HCI 1. mCPBA
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40%
(1) brevianamide B
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The completion of the synthesis of this fungal metabolite proved interesting in multiple 
ways. The structural characterization of synthetic brevianamide B allowed for the confirmation 
of the proposed structure for the original isolate. The development of both syn- and anti- 
selective SN2 cyclization methodologies allowed access to structural cores of indole alkaloids of 
both configurations. The SN2' cyclizations used in Williams' later [2.2.2]diazabicycle syntheses 
also gave improved yields and were exclusively selective for the syn-diastereomer (Scheme 
1.9).33
Scheme 1.9: SN2' cyclizations toward paraherquamide B and the stephacidins
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Biomimetic Intramolecular Hetero Diels-Alder Reaction:
As originally proposed by Porter and Sammes one year after the first isolation of 
brevianamide B, the biosynthetic formation of the [2.2.2]diazabicyclic core in this family of 
indole alkaloids is believed to occur via intramolecular hetero Diels-Alder (IMDA) reaction.34 
The proposed IMDA of a 5-hydroxypyrazine-2(lH)-one would provide a powerful and elegant 
means of establishing the desired core structure with simultaneous formation of two bonds 
(Scheme 1.10). The Williams group executed a second synthesis of brevianamide B 
incorporating the IMDA cyclization instead of their previously developed intramolecular SN2' 
cyclization methodology.35
Scheme 1.10: Intramolecular hetero Diels-Alder of a 5-hydroxypyrazine-2(lH)-one
OH
OH
brevianamide A
The Williams biomimetic IMDA brevianamide synthesis began with epi- 
deoxybrevianamide E (14) (Scheme 1.11). Conversion of 14 to its analogous diketopiperazine 
diene precursor proceeded in only two steps. First the diketopiperazine secondary amide was
Scheme 1.11: Synthesis of an IMDA precursor
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converted to its lactim ether 15. Lactim ether 15 was then oxidized with DDQ to IMDA 
precursor 16. Exposure of precursor 16 to aqueous KOH resulted in olefin isomerization to 
intermediate azadiene 17 which immediately underwent [4+2] cycloaddition with the readily 
accessible exocyclic alkene (Scheme 1.12). In this system, IMDA led to a 2:1 mixture of the 
undesired syn-diastereomer 18 and the o/it/'-diastereomer 19 with a combined yield of 60%. The 
desired minor product of this cyclization (19) was then quantitatively oxidized to its 
corresponding hydroxyindolenine 20. Finally, pinacol rearrangement and lactim ether 
deprotection affected the desired transformation of 20 to (±)-brevianamide B (1).
Scheme 1.12: IMDA and endgame for brevianamide B synthesis
MeCf
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(±)-brevianamide B (1)
The incorporation of an IMDA in the synthesis of brevianamide B marked the first use of 
the biomimetic reaction in the total synthesis of a natural product. While a complete total 
synthesis supported the possibility for a biosynthetic IMDA, the poor stereoselectivity during the 
cycloaddition and the necessarily racemic reaction products posed an obvious drawback of the
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approach. One noteworthy variation on this methodology was developed as an alternative to 
the basic conditions used by Williams in the brevianamide synthesis. Liebscher and coworkers 
pioneered alternative reaction conditions for accessing the [2.2.2]diazabicycle that involved 
neutral conditions (Scheme 1.13).36 Basic and neutral IMDA reactions have since been used in a 
number of natural product total syntheses.37
Scheme 1.13: Liebscher's IMDA study
HN
CHO
HNKOfBu
MOMMOM
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HO20 d 
48%
Oxidative Enolate Coupling Reaction:
After a successful series of investigations into the reactivity of enolated carbonyl 
functionalities with heterocyclic aromatic rings exposed to metal oxidants like Cu(ll), the Baran 
group demonstrated the potential utility of these developments in the syntheses of
[2.2.2]diazabicyclic alkaloids.38 In 2006, the Baran group reported the most recent total 
synthesis of stephacidin A (21) that incorporated their new oxidative enolate coupling method 
for creating [2.2.2]diazabicycles.39 This enantioselective ring formation effectively applied their 
oxidative coupling while providing improved synthetic yield of the diazabicyclic target and 
involved the intramolecular oxidative coupling of ester and amide enolates (Scheme 1.14). They 
predicted that the close proximity of sp2-hybridized a-carbons in the metal-bound transition 
state would drive reactivity and that the quaternary stereocenter of the proline ring would
25
contribute to facial selectivity of bond formation. In this manner, they achieved a highly 
selective synthesis of the natural product.
Scheme 1.14: Model oxidative enolate coupling to form [2.2.2]diazaoctane bicycles
Extensive effort led to the preparation of tryptophan and proline derived starting 
materials, 22 and 23 (Scheme 1.15). With both amino acid-derived components necessary for 
the stephacidin synthesis on-hand, reductive deprotection of the carboxybenzyl (Cbz) protecting 
group in 23 with palladium on carbon revealed proline methyl ester 24. Immediate exposure of 
24 to 22 with HATU allowed peptide coupling and prevented formation of the y-lactam 
corresponding to 24. Resulting amide 25 then underwent chemoselective Cbz deprotection, 
diketopiperazine ring closure, and /V-methoxymethyl (MOM) protection of the ring-closed 
secondary amide functionality. MOM-protected amide 26 was deemed an appropriate starting 
material for the key synthetic step and screening revealed Fe(acac)3 as the most effective metal 
oxidant for the reaction. Enolation of 26 with LDA and exposure to Fe(acac)3 provided 27 as a 
single diastereomer in 61% yield. Having successfully executed the stereoselective 
intramolecular oxidative enolate coupling to form the alkaloid's core [2.2.2]diazabicycle, the 
synthesis of stephacidin A only required a few more transformations. Coupling product 27 was 
MOM-deprotected, excess methyl Grignard converted the exocyclic methyl ester to a tertiary 
alcohol, and the alcohol intermediate was dehydrated to the corresponding alkene. Because 
instability of 28 under acidic conditions precluded Friedel-Crafts alkylation, sulfolane was used 
to facilitate thermolytic Boc deprotection and ring closure to form 21 in modest yield.
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Scheme 1.15: Completion of stephacidin A
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Aminoacyl Radical Cyclization:
In their synthesis of avrainvillamide (29) and stephacidin B (30) the Myers group applied 
an aminoacyl radical cyclization to form the alkaloid core structure.40 The application of this
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new approach marked the use of the fourth unique method for forming [2.2.2]diazabicycles in 
total syntheses. In synthesizing monomeric avrainvillamide, they also showed the ease with 
which 29 dimerizes to stephacidin B (30) in mild conditions.
The Myers synthesis began with cyclohexanone 31, a structure synthesized in two steps 
from commercially available materials (Scheme 1.16). Cyclohexanone 31 was deprotonated, 
facilitating the diastereoselective addition of novel electrophile 32 to the resulting enolate. 
Coupling product 33 was then converted to /V-Boc amino nitrile 34 through Strecker-like 
addition of hydrogen cyanide with reasonable diastereoselectivity. The a-carbon of ketone 34 
was epimerized by deprotonation with KHMDS in order to install the necessary stereochemistry 
of the target alkaloids and platinum catalyst 35 was used to convert 34's nitrile moiety to a 
primary amide. Thiophenol and triethylamine treatment of resulting primary amide 36 led to 
conjugate thiophenol addition as well as cyclic hemiaminal formation. Spirocyclic 37 was then 
dehydrated and its N-Boc protecting group was cleaved. Subsequent acylation of the 
deprotected pyrolidinyl amino group with radical precursor 38 produced amide 39. At this point 
amide 39 featured both a radical initiator and terminator in such a way that it could undergo the 
envisioned radical cyclization. Heating of amide 39 with tert-amyl peroxybenzoate in tert-butyl 
benzene resulted in homolytic bond cleavage to form aminoacyl radical intermediate 40. The 
radical formed in this homolytic cleavage quickly attacks the more substituted constituent of the 
enamide C-C double bond before it is finally trapped with the expulsion of the thiophenol radical 
acceptor. Radical cyclization gives [2.2.2]diazabicyclic avrainvillamide-precursor 41, for which 
transformation to the natural product proved relatively simple. 41 was converted to a-
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Scheme 1.16: Synthesis of avrainvillamide
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iodoenone 42 in three steps. Following these manipulations, a-iodoenone 42 underwent 
Ullman-like coupling with aryl iodide 43 to give nitroarene product 44. Reduction of 44 with 
activated zinc powder yielded the first synthetic target (-)-29, which could be easily converted to 
(+)-stephacidin B (30) in the presence of triethylamine.
Cation Olefin Cyclization:
The Simpkins lab employed a novel method for establishing [2.2.2)diazabicycles in a 
series of total syntheses including that of brevianamide B.41 The Simpkins' cation cascade 
sequence for creating the alkaloids' bridged diketopiperazine cores was envisioned to initiate via 
cation formation of an appropriately substituted DKP (Scheme 1.17). Prenyl trapping of the 
cation would result in bicyclo[2.2.2]diazaoctane core formation and would allow a second 
cyclization with the indole ring. This method promised a succinct means for accessing two rings 
of the indole alkaloids' core structure in a single operation.
Scheme 1.17: Cation olefin cascade cyclization
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The Simpkins synthesis of brevianamide B began with the coupling of prenylated proline 
45 to indole pyruvic acid 46 (Scheme 1.18). Hydroxy-DKP 47 then underwent cation olefin
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cyclization to establish both the bridged DKP core and adjacent gem-dimethyl 6-member ring of 
the diastereomeric products 48a and 48b. This reaction was observed with only moderate 
selectivity, giving a 4:1 ratio of epimers. It was hypothesized, but never investigated in this 
system, that more sterically bulky amide protecting groups would impart a stronger facial bias. 
The minor diastereomer, 48b, which corresponded to the bicyclic core of brevianamide B was 
then isolated and underwent a two-step sequence of peracid oxidation and base-catalyzed 
rearrangement to spiro-indoxyl bridged DKP 49b. Deprotection of 49b via reductive cleavage 
with Sml^LiCI led to problematic over-reduction of the indoxyl moiety, which then required 
oxidation with Dess-Martin periodinane to establish the target, brevianamide B (1). While the 
selectivity in this synthesis was moderate and favored the undesired diastereomeric bicycle, it 
did demonstrate a strong step-wise efficiency.
Scheme 1.18: Simpkins' synthesis of brevianamide B
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CHAPTER II
DEVELOPMENT OF DOMINO REACTION SEQUENCE 
Introduction and Retrosynthesis:
The primary goal of our initial studies was to develop a general and stereoselective
method for establishing bicyclo[2.2.2]diazaoctane cores that could be applied to multiple 
targets. We chose to pursue a diastereoselective intramolecular hetero-Diels-Alder (IMDA) 
because of the existing methods for forming the core structure, we were most impressed by 
Williams' IMDA.1 The Williams' IMDA had proven elegant in its powerful, concerted bond 
formation and so our main challenge would be to devise a method with which to execute the 
reaction stereoselectively.
As demonstrated in both the previously discussed brevianamide synthesis13 and a 
subsequent synthesis of stephacidin A (l) ,2f the reactive diketopiperazine (DKP) azadienes 
involved in the key [4+2] cycloadditions of these syntheses and nearly all of Williams' other 
syntheses are achiral (Scheme 2.1). Achirality in the intramolecular reaction of prestephacidin 2 
necessarily leads to a racemic mixture of cycloadducts (i)-stephacidin A (1) and its epimer, (±)-
Scheme 2.1: Racemic IMDA in synthesis of stephacidin A
OH OH
achiral DKP 
azadiene
NH OR
OR
OHdr 2.1:1OH
(+)-C6-ep/-stephacidin (3)(+)-stephacidin A (1)
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C6-ep/-stephacidin (3). These epimeric cycloadducts were isolated in a 2.1:1 diastereomeric 
ratio representative of similar achiral IMDA reactions. While biosynthetic studies suggest that 
achiral precursors are consistent with natural alkaloid biosyntheses, a weak diastereomeric ratio 
is not representative of the single enantiomeric series with which these metabolites are 
produced in nature. From a synthetic perspective, this suggests that by adhering closely to the 
presumed biosynthetic pathway, we may limit the potential to make [2.2.2]diazabicycles 
stereoselectively.
In contrast to the numerous racemic syntheses which involved achiral intermediates, 
Williams and coworkers also conducted asymmetric biomimetic IMDA syntheses of VM55599lc 
and versicolamide B.1' Unlike the precursors of related alkaloids, the reactive azadiene 
intermediates of the VM55599 and versicolamide B syntheses possess chiral centers at their 
spiro-oxindole and proline ring moieties respectively. The IMDA of versicolamide B precursor 
gave a racemic mixture of cycloadducts with a diastereomeric ratio of 1.4:1, suggesting that 
chirality at the spiro-oxindole functionality exerts little effect on facial preference of the IMDA. 
In contrast, the IMDA of VM55599 did demonstrate more reasonable facial preference with a 
diastereomeric ratio of 7.3:2.0, supporting the idea that chiral proline substituents could restrict 
access of a single azadiene face;
Previous work in the Scheerer research group has also probed the effect of chiral 
azadienes on the diastereoselectivity of the IMDA. In this investigation researchers 
characterized the thermal, intermolecular Diels-Alder cycloadditions of a readily prepared 
chiral, nonracemic DKP diene (4) with a variety of dieneophiles (Scheme 2.2).2 Azadiene 4 was 
synthesized in five steps from L-serineand featured a chiral t-butyl aminal. This sterically bulky 
aminal proved very effective in exerting diastereofacial control over the cycloaddition and could 
be removed following cyclization. In addition to the clear facial bias, cycloadditions of 4
36
Scheme 2.2: Diels-Alder cycloaddition of a chiral, non-racemic DKP diene
M  ♦v
NY ^  R3 *4
9 f-Bu
2 M+2] MeO
MeO 4
revealed a modest preference for the endo transition state and predictable regiochemistry with 
electron-rich or electron-deficient dienophiles, despite the dissonant charge affinity pattern of 
the azadiene. This predictable direction and subsequent cleavage encouraged the use of 
similarly bulky, removable substrates in our synthetic endeavors.
Interested in adapting our methodology to a targeted synthesis, we envisioned the 
IMDA of a possible malbrancheamide precursor 5 (Scheme 2.3).3 As in the previous 
intermolecular, chiral DKP Diels-Alder cycloadditions, we anticipated that the chiral aminal 
could effectively hinder one face of the diketopiperazine and drive dieneophile to approach 
exclusively to the opposite ring face during [4+2] cycloaddition. Although we still expected the
Scheme 2.3: Directed IMDA of chiral DKP azadiene 5
chiral DKP 
azadiene
NBOM
BOM
Cl
I [4+21 j f 4 +27
BOM
R
(+)-pre-malbrancheamide (6)
R
(+)-C6-epi- pre-malbrancheamide (7)
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formation of a C6-epimer (7) of our desired cycloadduct (6), we were curious to see which, how 
many, and in what diastereomeric ratio this reaction's cycloadducts would form.
Our initial model study focused on exploring the possibility of directed intramolecular 
hetero-Diels-Alder reactions of DKP-derived azadienes not necessarily related to natural 
products. Based on the numerous examples of syntheses and biosynthesis of
[2.2.2]diazabicycles, we recognized that the model IMDA precursor analogue of 5 must contain a 
chiral, non-racemic DKP azadiene coupled to an aromatic ring substituted with an alkene 
dieneophile. Fortunately, DKPs 8 and 9, formed in the same process as DKP-derived azadiene 4, 
and aromatic aldehyde 10 were easily prepared. While the t-butyl analog of 8 had been 
synthesized previously as a precursor to 4 and could have been used in this model reaction, 
difficulty in removal of the t-butyl group via acidic aminal hydrolysis in previous studies 
motivated the use of an alternative directing functionality. We anticipated the steric hindrance 
exerted by DKP diene-precursor 8's phenyfaminal to be comparable to that of the t-butyl aminal 
and valued the option to remove the phenyl directing group from our IMDA cycloadduct via 
reductive methods. We envisioned that the aldol condensation of 8 and 10 would afford 
coupling product 11 (Scheme 2.4). The isomerization of 11 under basic conditions would 
generate the azadiene intermediate 12, which would rapidly undergo IMDA. We hoped this 
synthetic sequence would generate model target [2.2.2]diazabicycle 18 with good 
diastereofacial selectivity and yield. We chose to conduct our model study with DKP 8 due to 
the abundance of this material over its epimer 9.
Methods and Results:
We began our model study with the preparation of DKP-lactim ether 8 in an analogous 
fashion to the synthesis of azadiene 4 (Scheme 2.5). /V-chloroacyl L-serine methyl ester was 
added to benzaldehyde dimethyl acetal with p-toluenesulfonic acid monohydrate to install the
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Scheme 2.4: Model Retrosynthesis for bicyclo[2.2.2]diazaoctane core
Ph
Ph
13
OMe
Ph
0
10 CHO
Ph
+
MeO
phenyl aminal auxiliary. Subsequent treatment with sodium azide led to halide displacement 
and the resulting intermediate azide underwent Staudinger reduction with resin-bound 
phosphine to afford diastereomeric cyclized products 8 and 9 in 36% and 19% yield, 
respectively. ^
'Scheme 2.5: Synthesis of DKP azadiene-precursors 8 and 9
O
c i ^ A NH
1. PhCH(OMe)2, 
TsOH, PhMe
2. NaN3, 80°
Me02C =■ H
OH 3. PPh3 resin, 
PhMe, 90°C
(yield of 3 steps)
 ’ 9 Ph ^rN^bN
MeO
H
8
36%
MeO
9
19%
The aromatic aldehyde 10 was easily prepared upon completion of 8. It was quickly 
recognized that a so called "domino" sequence of the desired transformations was occurring 
under a single set of conditions (Scheme 2.6). When left to reflux under basic conditions for 24 
hours, DKP 8 and salicylic aldehdye 10 yielded [2.2.2]diazabicycle 13 in good yield (76%) and 
with excellent diastereoselectivity (dr 95:5). X-ray crystallographic analysis revealed the
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absolute configuration of this molecule/ confirming the facial preference of the azadiene to 
engage the ring face opposite the phenyl aminal in cycloaddition.
Scheme 2.6: Domino reaction sequence
H Ph
Ph .OMeNaOMe
MeOH
CHO
+
65°C
76% yield 
dr 95:5
MeO
aldol condensation
Ph
Ph
H
alkene
isomerization
OMe
OMe
To achieve this domino reaction sequence, basic conditions first affected enolization of 
the amide functionality of DKP 8, allowing aldol addition and condensation to intermediate 11. 
The same basic conditions then caused alkene isomerization to reactive azadiene 12 which 
underwent thermal IMDA cycloaddition. Satisfied with the yield, diastereomeric ratio, and ease 
of operation of our model synthesis, we shifted our synthetic efforts toward the natural 
product, malbrancheamide B.
In summary, we successfully employed a novel diaStereofacially selective IMDA 
cycloaddition in the synthesis of a model [2.2.2]diazaoctane bicycle. The originally envisioned 
two-step, three-transformation model sequence was found to instead occur in a single pot with 
good yield (76%) and excellent diastereoselectivity (95:5). We attribute the observed 
diastereofacial bias to a non-racemic, chiral phenyl aminal auxiliary on the DKP-derived azadiene
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component of the [4+2]. Pleased with the reliable reactivity and selectivity, we next set out to 
adapt this reaction sequence to the total synthesis of malbrancheamide B.
Experimental Section:
General Information. All reactions were carried out under an atmosphere of nitrogen in flame- 
dried or oven-dried glassware with magnetic stirring unless otherwise indicated. Acetonitrile, 
THF, toluene, and Et20  were degassed with argon and purified by passage through a column of 
molecular sieves and a bed of activated alumina.4 Dichloromethane was distilled from CaH2 
prior to use. All reagents were used as received unless otherwise noted. Flash column 
chromatography5 was performed using SiliCycle siliaflash P60 silica gel (230-400 mesh). 
Analytical thin layer chromatography was performed on SiliCycle 60A glass plates. Visualization 
was accomplished with UV light, anisaldehyde, eerie ammonium molybdate (CAM), potassium 
permanganate, or ninhydrin, followed by heating. Film (or KBr pellet) infrared spectra were 
recorded using FTIR spectrophotometer. Optical rotations were determined by digital 
polarimeter at 25 °C. 1H NMR spectra were recorded on a 400 MHz spectrometer and are 
reported in ppm using solvent as an internal standard (CDCI3 at 7.26 ppm) or tetramethylsilane 
(0.00 ppm). Proton-decoupled 13C-NMR spectra were recorded at 100 MHz spectrometer and 
are reported in ppm using solvent as an internal standard (CDCI3 at 77.00 ppm). All compounds 
were judged to be homogeneous (>95% purity) by *H and 13C NMR spectroscopy unless 
otherwise noted as mixtures. Mass spectra data analysis was obtained through positive 
electrospray ionization (ICR-MS w / NaCI). HPLC was performed using a binary gradient 
(acetonitrile, water with 0.1% TFA) and peak detection was accomplished with photodiode 
array.
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Experimental Procedures.
C k X  2. NaN3) 80°C
1. PhCH(OME)2, 
0  TsOH, PhMe Ph
J s ^ O H  3. PPh3 resin, 
A PhMe, 90°CMe02C MeO
O
(yield of 3 steps) 8
36%
9
19%
Diketopiperazine tactim methyl ether 8, 9. To /V-chloroacyl L-serine methyl ester6 (4.5 g, 22.8 
mmol) in toluene (220 mL) at rt was added benzaldehyde dimethyl acetal (2.9 ml, 27.4 mmol) 
and p-toluenesulfonic acid monohydrate (108 mg, 0.57 mmol). The solution was heated at reflux 
for 16 h with a Dean-Stark trap. After cooling to rt, the solution was diluted with saturated 
aqueous NaHC03 (2 x 50 ml). The organic layer was removed and the aqueous portion extracted 
with Et20  (75 ml). The combined organic layers were washed with brine (50 ml), dried with 
Na2S04, and concentrated in vacuo. The viscous product was purified by flash column 
chromatography on silica gel (elution: 10% to 60% EtOAc in hexane) to afford a yellow oil (5.48
g, 19.23 mmol, dr ca. 2:1). This intermediate product was dissolved in butanone (110 ml), 
sodium azide (2.50 g, 38.5 mmol) was added, and the heterogenous mixture was heated to 80 
°C for 15 h. After cooling to rt, the mixture was concentrated to a syrup and diluted with a half­
saturated NaCI solution (100 ml) and extracted with Et20  (3 x 50 ml). The combined organic 
phases were dried with Na2S04, and concentrated to afford a reddish-brown oil (5.34 g, 18.3 
mmol). This intermediate azide product was used without purification in the subsequent 
Staudinger reduction. After dissolving the intermediate azide product (2.3 g, 7.9 mmol) in 
toluene (45 ml), resin-bound triphenyl phosphine (3.3 g, ~10.0 mmol) was added at rt. The 
mixture was stirred for 10 min at rt until gas evolution steadied and was heated to 90 °C for 20
h. Additional resin-bound triphenyl phosphine was added (0.5 g), until consumption of the 
starting material was apparent by TLC. After cooling to rt, the phosphine resin was removed by
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vacuum filtration. The filtrate was concentrated and purified by flash column chromatography 
on silica (elution: 30% to 100% EtOAc in hexane) to afford product 8 (0.88 g, 36% yield, 3 steps) 
as a colorless solid and 9 (0.44 g, 19% yield, 3 steps) as a light yellow oil:
8: mp 133 °C; TLC (60% EtOAc in hexane), R/: 0.15 (KMn04); [a]D25 = -63.2° (c = 2.02, CH2CI2); IR 
(film) 3022, 2948, 2872, 1684,1559, 1361, 1265, 1185, 1048, 934, 760 cm"1; JH NMR (400MHz, 
C0CI3) 7.37 (m, 3H), 7.29 (m, 2H), 6.25 (s, 1H, C8H), 4.49 (m, 1H), 4.31 (m, 1H), 4.28 (d, J = 19.5 
Hz, 1H), 4.12 (dd, J = 19.9, 3.9 Hz, 1H), 4.04 (t, J = 9.0 ,1H, C6H), 3.83 (s, 3H); 13C NMR (100 MHz, 
CDCI3) 6 166.0, 161.3, 136.9, 129.6, 128.9, 126.8, 90.2, 65.7, 55.1, 54.1, 53.6; Exact mass calcd 
for C13H14N20 3Na [M+Na]+, 269.0897. Found 269.0892.
9: TLC (60% EtOAc in hexane), Rf: 0.20 (KMn04); [a]D25 -  -107° (c = 2.30, CH2CI2); IR (film) 2993, 
2950, 2892,1704,1438,1338,1315,1224,1113,1011, 850, 769 cm"1; JH NMR (400 MHz, CDCI3) 
7.50 (m, 3H), 7.40 (m, 2H), 6.50 (s, 1H, C8H), 4.49 (dd, obs triplet, J *  6.6 Hz, 1H), 4.37 (m, 1H), 
4.23 (s, 2H), 3.88 (t, J = 9.0 Hz, 1H, C6H), 3.76 (s, 3H); 13C NMR (100 MHz, CDCI3) 6 165.4, 158.6,
138.2, 129.3, 128.8, 126.5, 88.9, 69.4, 54.3, 53.8, 52,2; Exact mass calcd for C13H14N20 3Na 
[M+Naf, 269.0897. Found 269.0901.
NaOMe
MeOH
76% yield 
dr 95:5
Cycloadduct 13. To a solution of compound 8 (40.4 mg, 0.25 mmol) in methanol (2.00 mL) 
under nitrogen was added salicaldehyde 10 (57.1 mg, 0.23 mmol) and sodium methoxide (0.37 
mL, 2M, 0.75 mmol). The reaction vessel was fitted with a reflux condenser and heated to 65 °C. 
After stirring at reflux for 21 h, the mixture was cooled to 23 °C, diluted with sat. aqueous NH4CI 
and extracted with EtOAc (4 x 15 mL). The combined organic layers were washed with brine,
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dried with sodium sulfate, and concentrated in vacuo. The unpurified product was a single 
diastereomer as judged by *H NMR spectroscopy. Purification by flash chromatography on silica 
gel (elution: 20% to 60% EtOAc in hexane) afforded product 13 (68.7 mg, 76% yield) as a 
colorless amorphous solid: TLC (40% EtOAc in hexane), Rf: 0.40 (CAM); [a]D25 = -75.3° (c = 0.77, 
MeOH); IR (film) 2948, 2865, 1691, 1633,1490,1289 cm-1; XH NMR (400 MHz, CDCI3) 7.38-7.35 
(m, 3H), 7.32-7.28 (m, 3H), 7.18 (t, J = 7.4 Hz, 1H), 7.05 (t, J = 7.4 Hz, 1H), 6.97 (d, J = 7.8 Hz, 1H),
6.26 (s, 1H), 4.51 (d, J = 9.3 Hz), 4.06 (dd, J = 11.7, 3.9 Hz, 1H), 4.02 (d, J = 9.4 Hz, 1H), 3.63 (s, 
3H), 3.49 (d, J -  14.9 Hz, 1H), 3.42 (d, J = 14.9 Hz, 1H), 3.28 (t, J = 11.7 Hz, 1H), 2.77 (m, 1H), 2.35 
(dd, J = 12.9, 9.8 Hz, 1H), 1.00 (dd, J = 12.9, 4.7 Hz, 1H); 13C NMR (100 MHz, CDCI3) 6 170.5,
168.9,159.0,136.4,132.5,131.3,129.2,128.5,127.5,126.3,123.9,120.2, 88.4, 70.7, 67.2, 66.0,
62.5, 54.5, 43.0, 36.6, 32.9); HRMS (ES+): Exact mass calcd for C23H22N20 4Na [M+Na]+, 413.1472. 
Found 413.1470.
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CHAPTER III 
SYNTHESIS OF MALBRANCHEAMIDE B 
Introduction to  Malbrancheamides:
The malbrancheamide family of diazabicyclic alkaloids was one of the most recently
discovered groups containing a [2.2.2]diazabicyclic core. Malbrancheamide and 
malbrancheamide B were originally isolated together from Malbranchea aurantiaca RRC1813 by 
the Mata group in 2006 (Figure 3.1).1 These molecules represented the first members of the 
alkaloid family to be isolated from a species not belonging to the genii of Aspergillus or 
Penicillium and were the first to contain halogenation. Both of these molecules demonstrate 
moderate biological activity as concentration-dependent calmodulin inhibitors of CaM-
Figure 3.1: The malbrancheamide family of alkaloids
malbrancheamide malbrancheamide B
premalbrancheamide (+)-malbrancheamide C (+)-isomalbrancheamide C
(-)-spiromalbramide (+)-isomalbrancheamide B
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dependent phosphodiesterase (PDE1).2 The Mata group later isolated an additional family 
member, the nonhalogenated premalbrancheamide, from the same fungal species of 
Malbranchea. In 2011, Crews and coworkers identified (-)-spiromalbramide and (+)- 
isomalbrancheamide B, two novel chlorinated [2.2.2]diazabicycles from Malbranchea 
graminicola UCSC 086937A.3 The Crews group also isolated brominated analogues of 
malbrancheamide B and (+)-isomalbrancheamide B upon fungal growth on bromine-enriched 
medium. These brominated bicycles were named (+)-malbrancheamide C and (+)- 
isomalbrancheamide C.
Compared to related alkaloids like the stephacidins, the malbrancheamides 
demonstrate little structural diversity. Structural features include a monoketopiperazine core, 
bicycles of the more prevalent syn-conformation, and unsubstituted proline-derived rings. Only 
spiromalbramide contains a spirocyclic ring fusion pattern resembling the spiro-oxindoles of the 
marcfortines, paraherquamides, and notoamides. Structural variations between the 
malbrancheamides occur mainly in their indole halogenation patterns. All the 
malbrancheamides except premalbrancheamide exhibit either indole monohalogenation at the 
C-5 or C-6 position or indole dihalogenation at both C-5 and C-6. This halogen substitution 
feature is unique among the family of [2.2.2]diazabicycles and suggests a biogenic halogenation 
pathway exclusive to the Malbranchea genus.
Investigation into the biosyntheses of the malbrancheamides has largely focused on the 
timing of the indole halogenation and the sequence of diketopiperazine reduction to 
monoketopiperazine core and intramolecular hetero-Diels-Alder (IMDA).4 The first proposal for 
a biosynthesis of the malbrancheamides began with the condensation of L-tryptophan, L- 
proline, and dimethylallyl pyrophosphate (DMAPP) to deoxybrevianamide E (Scheme 3.1). At
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this point oxidation to either the reactive azadiene intermediate 5-hydroxypyrazin-2(lM)-one or 
its carbonyl-reduced analog would allow the IMDA to keto-premalbrancheamide or 
premalbrancheamide respectively. In the event that IMDA occurs prior to carbonyl reduction, 
keto-premalbrancheamide would then be reduced to premalbrancheamide, which would in turn 
lead to two successive halogenations, first to malbrancheamide B, then to malbrancheamide. 
Precursor incorporation studies with doubly 13C-labeled premalbrancheamide and keto- 
premalbrancheamide by the Williams group showed that of the two potential precursors, only 
13C-labeled premalbrancheamide is incorporated into malbrancheamide B by Malbranchea 
aurantiaca. This observation suggests that carbonyl reduction precedes [4+2] cycloaddition 
which is followed by indole chlorination to malbrancheamide B and malbrancheamide.
Scheme 3.1: A proposed unified biosynthesis of the malbrancheamides
[ > - C 0 2 H
N
H
H H 'a, X = 0
b, X *  H2
H
deoxybrevianamide E
H
IMDA halogenase
keto-premalbrancheamide premalbrancheamide malbrancheamide B
H
halogenase
malbrancheamide
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Previous Syntheses:
In a 2008 report, Williams and coworkers reported the first synthesis of 
malbrancheamide.5 At the time, the absolute structural configuration of malbrancheamide B 
was unknown and as a result the authors chose to target three molecules through parallel 
syntheses. The first target for synthesis was the known dihalogenated malbrancheamide. The 
authors recognized that malbrancheamide B was halogenated at either the indole 5- or 6- 
position. To establish the configuration of the monohalogenated malbrancheamide B, the 
authors chose to synthesize both 5- and 6-chloroindoles for comparison with natural samples.
These syntheses began by building around indoles which could be easily halogenated in 
the 5- or 6-position. The three varieties of chlorinated indoles were functionalized with reverse 
prenyl groups at the 2-position of the ring system (Scheme 3.2). These reverse-prenylated 
indoles were then converted to gramines, which in turn were converted into their 
corresponding tryptophan derivatives and Boc-protected at the free amine moiety. Ester 
hydrolysis led to the formation of tryptophan-derived acids (Scheme 3.3). Having already 
incorporated tryptophan and isoprene-derived units into the hetero-Diels-Alder precursor, the 
sole remaining component required for a biomimetic approach was a proline-derived unit. To
Scheme 3.2: Synthetic scheme of reverse prenylated tryptophan derivatives
Me2NH
C02Et
1. 0.5 M NaOH, Boc20  
NH2 diox., H2Q_______
'2 '
NHBoc
C02H
r r z r — :— ^  x
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this end, the tryptophan-derived acids were coupled with c/s-3-hydroxyproline ethyl ester and 
deprotected, allowing immediate cyclization to the corresponding diketopiperazines. 
Dehydration of these products yielded the appropriate IMDA substrates, cyclization of which 
gave a separable mixture of [2.2.2]diazaoctane bicycle diastereomers. Selective reduction of 
these [2.2.2]bicycles with Dibal-H produced the three desired targets at which point the 
absolute structure of malbrancheamide B was verified by comparison to synthetic material. 
These biomimetic syntheses are elegant and concise, but possess the obvious drawback of 
intercepting an achiral azadiene IMDA substrate resulting in a racemic mixture of 
[2.2.2]diazaoctane bicyclic adducts.
Scheme 3.3: Formation of [2.2.2]diazabicycle
Simpkins and coworkers reported the enantioselective total synthesis of ent- 
malbrancheamide B in 2009.6 Model studies from the Simpkins lab revealed that the [2.2.2]- 
diazabicyclic core could be accessed with desired stereoselectively by cation olefin cyclization 
from a suitable diketopiperazine precursor via a-amido A/-acyliminium species intermediate.7 To 
apply this novel cylization methodology, Simpkins elected to initially target (-)-enT- 
malbrancheamide B, the unnatural stereoisomer, primarily because of the low cost of the 
corresponding L-proline.
The Simpkins synthesis, much like the Williams synthesis, began from an indole nucleus; 
the illustrated Boc-protected 6-chlorocarboxaldeyde was easily prepared from commercially 
available materials (Scheme 3.4).6 Aldol addition of this formylated indole nucleus to a methyl 
ester led to an alcoholic aldol adduct. Dehydration and saponification of this aldol product led 
to the corresponding carboxylic acid which was then bonded to a prenylated proline derivative 
via standard amino acid coupling. At this point, all three essential components of the natural 
product, tryptophan, proline, and an isoprene unit, have been incorporated. Deprotection of
Scheme 3.4: Synthetic preparation of [2.2.2]diazaoctane-precursor
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the remaining protected enol with CBr4 in warm isopropyl alcohol delivered the key 
diketopiperazine cyclization precursor necessary for the planned cation olefin cyclization. Upon 
treatment with trimethylsilyl triflate, both the indole N-Boc protecting group was cleaved and 
the [2.2.2]diazaoctane bicycle was formed in 4:1 mixture of epimers favoring the desired 
product in 64% yield (Scheme 3.5). The product of reductive cleavage of the remaining BOM 
protecting group was the same diketopiperazine bicycle made in Williams' malbrancheamide 
synthesis. Following Williams' precedent, Simpkins employed a Dibal-H reduction to form (-)- 
ent-malbrancheamide B.
Scheme 3.5: Cation olefin cyclization
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Previous research into [2.2.2]diazaoctane bicycles proved very useful in our pursuit of 
malbrancheamide B. Having five strategies for installing the core structural motif at our disposal 
and comparing the strengths and weaknesses of two excellent existing syntheses of our target 
provided great insight. Inspired by the elegance of the biomimetic approach to establishing the 
core structure, we chose to pursue a modified version of Williams' biomimetic approach in 
which the incorporation of a chiral, nonracemic DKP-derived azadiene into the key IMDA would 
impart diastereofacial bias.
Enantioselective Retrosynthesis:
We constructed the restrosynthesis of our enantioselective route to (+)- 
malbrancheamide B upon the effective demonstration of the directed domino reaction 
sequence in a model system (Scheme 3.6). We anticipated that malbrancheamide B (1) could be
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accessed directly through palladium-catalyzed reduction of oc,0-unsaturated aldehyde (2), an 
intermediate which could be synthesized from domino reaction product 3 in a series of 
functional group transformations aimed at removing the aminal directing group essential to the 
domino sequence, but not present in the natural product. The domino sequence itself would be 
the crux of our synthetic plan, establishing the core structure as previously discussed through 
the one-pot aldol condensation, alkene isomerization, and intramolecular hetero-Diels-Alder 
cyclization. Finally, we knew that the domino reaction substrates 4 and 5 could also be easily 
prepared as the necessary preparatory precedent had almost entirely been established already.
Scheme 3.6: Retrosynthetic plan for enantioselective synthesis
NBn
HOHO
ClCl
BOMH1
CHO
OMe
Cl
BOM
C>
Cl
BOM
Methods, Results, and Total Enantioselective Synthesis:
In the forward sense, the first phase of the enantioselective synthesis was the 
preparation of appropriate indole carboxaldehyde and DKP azadiene-precursor components 
necessary for a domino reaction sequence. This necessitated a 4-step synthesis of the modified 
chloroindole 4. These transformations mainly followed the procedures developed by Williams in 
his biomimetic malbrancheamide synthesis and converted the commercially-available 6-
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chloroindole to our desired product (Scheme 3.7).5 No additional synthetic effort was necessary 
in the preparation of an appropriate diketopiperazine since chiral, nonracemic phenyl- 
substituted DKP-precursor 5 was available in appreciable quantities following our model study 
(Chapter II).
Scheme 3.7: Preparation of BOM-protected chloroindole 4
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The union of BOM-protected indole 4 and phenyl-functionalized DKP 5 was achieved on 
exposure to basic conditions at reflux overnight (Scheme 3.8). The resulting domino reaction 
sequence yielded an inseparable mixture of two diazabicyclic cycloadducts, 3a and 3b, in a 1:2 
ratio as estimated by *H NMR spectroscopy with a combined yield of 85%. Not only did this 
result confirm that the conditions employed were sufficient in affecting enolization in the DKP 
substrate and isomerization in the aldol condensate, but it also suggested that the chiral phenyl 
aminal on the DKP azadiene-precursor was effective in controlling facial accessibility in the 
intermediate azadiene. At this time it was unclear whether the phenyl aminal exerted any 
control over the facial accessibility of the alkene, but the 2:1 ratio of diastereomers observed 
from this reaction was consistent with those of multiple racemic syntheses of the Williams
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Scheme 3.8: Domino cyclization in the enantioselective synthesis of malbrancheamide B
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group.2 The question of the aminal's role in facial preference would eventually be further 
illuminated upon the completion of an analogous racemic domino reaction sequence. In spite of 
the successful coupling of BOM-protected indole 4 and DKP 5 into a [2.2.2]diazabicycle, the 
challenge of separating these cycloadducts proved overly difficult. Failure to isolate the major 
diastereomeric product of the cycloaddition following multiple attempts at separation by 
chromatography on silica gel forced the progression of the synthesis with the existing 1:2 
mixture of diastereomers. Conversion of the diastereomeric mixture to a separable mixture of 
diketopiperazines required one additional step. Initially, reaction with TMSI was employed as 
the preferred method of cleaving the cycloadducts' lactim methyl ether. Although this method 
proved successful in derivatizing the lactim methyl ether with acceptable yields at first pass, the
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success of this method was inconsistent. As an alternative, exposing the diastereomers to mild 
acidic conditions with equimolar quantities of TsOHH20 in CH2CI2 followed by basification 
allowed for an identical conversion. These acidic conditions affected the desired imine 
hydrolysis more consistently than TMSI. It was also observed through repetitions at room 
temperature and 0°C that imine hydrolysis at higher temperature led to hydrolysis of the indolic 
BOM group. This additional hydrolytic cleavage was avoided in the total synthesis as eventual 
experience with both protected and unprotected materials revealed that preservation of the 
BOM group led to improved solubility of later malbrancheamide precursors in most organic 
solvents. The mixture of BOM-protected diketopiperazines 6a and 6b could be easily separated 
by flash column chromatography on silica gel, but was achieved more efficiently by selective 
precipitation of 6b through recrystallization of the mixture (60% yield).
The focus of our synthetic effort after establishing the diketopiperazine bicycle of 6b 
was to establish the monoketopiperazine characteristic of the targeted natural product through 
selective reduction of the tertiary amide. Treatment with Dibal-H realized the desired 
transformation and also revealed the benzyl amine and primary alcohol functionalities of 7 as a 
result of the decomposition of the aminal auxiliary. At this point, we anticipated that four 
remaining transformations would be required to complete the synthesis of malbrancheamide B. 
As we envisioned utilizing the Horner-Wadsworth-Emmons olefination to affect a two carbon 
extension of the chain opened upon Dibal-H treatment, it was necessary to oxide (S03pyr, 
DMSO, Hiinig's base) alcohol 7 to the corresponding aldehyde 8.
The newly formed aldehyde 8 was an appropriate substrate for Horner-Wadsworth- 
Emmons olefination under soft enolization conditions8 and was coupled with phosphonamide 9 
to form Weinreb amide 10 (Scheme 3.9). This reaction proved sufficient in extending the Cl
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chain by the two carbons required to form the target's pyrrolidine ring. With the requisite chain 
length installed, we next performed the reduction of amide 10 to corresponding a,(5- 
unsaturated aldehyde 11 in order to set the stage for the planned cyclization strategy via 
palladium-catalyzed reduction cascade.
Scheme 3.9: Anticipated HWE, reduction and hydrogenation to (+)-malbrancheamide B
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We hoped that upon exposure to H2 and Pd/C, aldehyde 11 would undergo several 
transformations, ultimately resulting in the formation of malbrancheamide B. We anticipated 
that BOM cleavage and hydrogenation of the a,|3-unsaturation would occur rapidly to form 
intermediate 12. Saturated aldehyde 12 would itself undergo benzyl cleavage followed quickly 
by cyclization to form (+)-malbrancheamide B (1). Initially, a small amount of the unsaturated 
aldehyde 11 was used to probe the palladium reduction cascade. The crude NMR spectral 
data collected on this reaction product suggested that while the cascade was executing the 
desired transformations, it was also effecting the removal of the C6-indole chlorination (Scheme
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3.10). Manipulations of the reaction conditions yielded no success in preserving the halogen. 
While ineffective in completing the synthesis, these reactions did yield high resolution mass 
spectrometry hits which supported our identification of the product as a des-chloro analog of 
the targeted natural product. Since loss of halogen proved unavoidable with catalytic 
hydrogenation, we returned to aldehyde 8 and pursued an alternative reductive strategy for 
completing the synthesis.
Scheme 3.10: Observed hydrogenation of 11 to premalbrancheamide
NBn
HO HOo Pd/c, H2, MeOH
Cl
BOM premalbrancheamide
CHONBn
HO HO
H (+)-1Cl
Our experience working through the first attempted endgame informed us that 
aldehyde 8 was suitable for extension through Horner-Wadsworth-Emmons. Since the main 
advantage of Weinreb amide was the ease with which it could be converted to the a,(3- 
unsaturated aldehyde, we chose to replace phosphonamide 9 for phosphonacetate 14. This 
revised Horner-Wadsworth-Emmons led to the formation of a,{3-unsaturated methyl ester 15 
(Scheme 3.11). We anticipated that reduction of the a,(3~unsaturation in 15 would allow 
subsequent cyclization to a pyrollidine ring. Sodium borohydride was selected to perform this 
1,4-hydride reduction and proved competent, but at first attempt led to a 2:1 formation of
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Scheme 3.11: Amended route for the completion of (+)-malbrancheamide B
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allylic alcohol 16 over the desired saturated alcohol 17. Unsatisfied with this ratio of products, 
further effort was devoted to finding preferable conditions and eventually the formation of 
allylic alcohol was minimized. Under these optimized conditions, saturated alcohol 17 could be 
isolated in 58% yield. Our supply of the desired alcohol was supplemented by a diimide 
reduction of the allylic alcohol converted undesired byproduct 16 to 17.
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With an extended Cl chain in hand, our synthetic focus transitioned to achieving the 
cyclization forming the pyrollidine ring. To complete this transformation, the primary saturated 
alcohol 17 was first activated through mesylation. We had anticipated that the displacement of 
this mesylate by the non-bonding pair of electrons o f the benzyl amine in an intramolecular N- 
alkylatron would happen at room temperature, but it turned out that the ambient temperature 
was insufficient to drive this change. The mesylate was heated to 120 °C in a sealed tube with 
toluene in order to achieve /V-alkylation and form the desired quaternary salt 18. After 
formation of 18 was completed, Kl and triethylamine were added to mixture, the tube was 
returned to heat (120°C) for 20 hours, completing the dealkylation of the benzyl functionality. 
Finally, (+)-malbrancheamide B (1) was formed through the deprotection of the indole using the 
mild TsOH H20  developed previously.
Racemic Retrosynthesis:
Having completed the total enantioselective synthesis of (+)-malbrancheamide B, we 
were pleased with the facial selectivity of our IMDA cyclization and wanted to demonstrate the 
brevity with which a racemic synthesis using the domino reaction sequence could be achieved. 
The retrosynthesis built around this racemic domino reaction sequence involved only four 
transformations (Scheme 3.12). In the forward sense we planned to couple the indole
Scheme 3.12: Retrosynthetic plan for racemic synthesis
Q
Cl
1 H BOM 4 BOM
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dieneophile 4 to an achiral diketopiperazine diene-precursor 19, then convert the resulting 
cycloadduct to the diketopiperazine analog 19, which could be deprotected and, following 
removal of the BOM-group, directly reduced using published precedent to the racemic natural 
product.
Methods, Results, and Formal Racemic Synthesis:
The BOM-protected chloroindole 4 was prepared in previous synthetic work leaving only 
the synthesis of the achiral diketopiperazine demanded by the planned domino sequence. This 
simplified alternative to the diene-precursor used in our enantioselective synthesis was 
prepared in only 3 steps from proline methyl ester with a single chromatographic separation in 
80% yield. This DKP substrate 20 was then coupled to chloroindole 4 under the same basic 
conditions employed in all our other domino reactions.
The anticipated result of the racemic domino reaction sequence were IMDA 
cycloadducts 21a and 21b, racemic cycloadducts resulting from the achiral nature of the 
intermediate formed (Scheme 3.13). Unlike in any other domino reaction sequence however, 
the diketopiperazine 21c was also consistently observed as a product of this reaction. The 
presence of this third, unexpected product suggests that in addition to the envisioned domino 
pathway, the lactim functionality of 21b was consistently and selectively hydrolyzing to the 
diketopiperazine. The yield of these three products was nearly quantitative and the ratio of syn- 
configured cycloadducts 21b and the derived DKP 21c to anti-configured product cycloadduct 
21a, was 2.3:1 as judged by JH NMR spectroscopy. This result meant that since the syn- 
configured cycloadduct was hydrolyzing exclusively, both 21b and 21c could be advanced 
toward the similarly syn-configured malbrancheamide B.
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Scheme 3.13: Racemic domino reaction sequence towards malbrancheamide B
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Satisfied that the results of the domino sequence had been thoroughly accounted for, 
we used the chemistry established in our enantioselective synthesis of malbrancheamide B to 
convert both racemic syn-configured cycloadducts to oxo-malbrancheamide B (22) under mild 
acidic conditions (Figure 3.14). In 21b, this involved the deprotection of both the lactim O- 
methyl ether and the BOM-group on the indole, and in 21c, which had already been converted 
from lactim ether to DKP, the acidic conditions only served to cleave the BOM functionality. 
These two reactions proved reliable in synthesizing oxo-malbrancheamide B (87% from 21b; 
61% from 21c), and given that this product was the penultimate precursor to the 
monoketopiperazine natural product in Williams' synthesis, we felt content with the completion 
of a formal synthesis.5
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Figure 3.14: Endgame of racemic synthesis
i. TsOH H20
ii. NaHC03; PhMe, heat
87%
HO
Cl
22
21c
i. TsOH H20
ii. NaHC03; PhMe, heat
61%
HO
Cl
22
Dibal-H 
22  ►  1
Lit. 74%
Conclusions:
The total enantioselective of (+)-malbrancheamide B and an analogous racemic 
synthesis are reported. In both cases, the core [2.2.2]diazabicycle of the natural product was 
established via domino reaction sequence involving aldol condensation, isomerization, and 
IMDA. In the case of the enantioselective synthesis, a chiral aminal auxiliary on the IMDA- 
precursor introduced via a chiral, non-racemic DKP diene-precursor enforced complete 
diastereofacial control over the cycloaddition.
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Experimental Section:
CHO
^  (COCI)2,
xx— 1 DMF _
BOMCI
►
DMF ClCl H CH2CI2 C|
Chloroindole 4. Oxalyl chloride (1.00 mL) was added to DMF (0.95 mL) and CH2CI2 (31 mL) at CfC 
and the solution was allowed to stir for 15 minutes at CfC. 6-Chloro-2-(2-methylbut-3-en-2-yl)- 
lH-indole-3-carbaldehyde5 (1.641 g, 7.47 mmol) was dissolved in CH2CI2 (21 mL) and transferred 
to the oxalyl chloride solution over 2 min via syringe. The reaction mixture was allowed to stir at 
CfC for 5 min and the cooling bath was removed. After stirring 1.5 h at rt, the mixture was 
concentrated to a volume of ~5 mL and THF (10 mL), NaOH (10 mL), and H20 (10 mL) were 
added. The biphasic mixture was stirred rapidly for 2 h, Et20  was added (15 mL) and the organic 
layer removed. The aqueous layer was extracted with additional Et20  (3 x 15 mL). The combined 
organic layers were washed with brine, dried (Na2S04), and concentrated in vacuo. 
Recrystallization (MeOH/toluene) of the white powder afforded l “((benzyloxy)methyl)-6-chloro- 
2-(2-methylbut-3-en-2-yl)-lH-indole-3-carbaldehyde (910 mg, 49% yield) as colorless needles: 
mp 227 °C; TLC (10% EtOAc in hexane), Rf: 0.40 (CAM); IR (KBr pellet) 1628, 1577, 1457, 1378, 
1352, 1294, 1179, 1147, 1102, 1061, 1104, 964, 922 cm"1; XH NMR (400 MHz, CDCI3) 10.45 (s, 
1H), 8.34 (s, 1H), 8.28 (d, J = 8.6 Hz, 1H), 7.35 (d, J = 1.6 Hz, 1H), 7.24 (dd, J = 8.6, 2.0 Hz, 1H), 
6.22 (dd, J = 17.6, 10.6 Hz, 1H), 5.32 (d, J = 2.0 Hz, 1H), 5.29 (d, J = 8.6 Hz, 1H), 1.73 (s, 6H); 13C 
NMR (100 MHz, MeOD) 210.2, 188.7, 159.0, 147.5, 137.1, 130.1, 126.9, 124.2, 123.8, 113.5, 
112.7, 41.4, 30.8, 29.5 6. Exact mass calcd for C14H14CINONa[M+Na]+, 270.0656. Found 
270.0656.
To a dry flask was added NaH (57-63% disp. on oil, 71.2 mg, ca. 1.75 mmol) and DMF (1.6 mL). 
The reaction vessel was cooled to 0 °C and l-((benzyloxy)methyl)-6-chloro-2-(2-methylbut-3-en-
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2-yl)-lH-indole-3-carbaldehyde (141.0 mg, 0.569 mmol) was added as a solid in three portions 
(gas evolution). The reaction mixture was stirred for 5 min, and then benzyl chloromethyl ether 
(tech grade 75%, 0.471mL, 3.39 mmol) and tetrabutyl ammonium iodide (43.7 mg) were added. 
The mixture was brought to room temperature over 1 h while stirring. The reaction mixture was 
diluted with saturated aqueous NH4C1 and extracted with EtOAc (4 x 10 ml). The combined 
organic portions were washed with brine, dried (Na2S04), and concentrated in vacuo. The 
resulting residue was purified by flash chromatography on silica gel (elution: 15% to 30% EtOAc 
in hexane gradient) to afford the protected indole 4 (185.2 mg, 88% yield) as a light yellow oil: 
TIC (20% EtOAc in hexane), R/: 0.45 (CAM); IR (film) 1642, 1608,1578,1507,1474,1414, 1374, 
1333, 1215,1153, 1133 cm"1; NMR (400 MHz, CDCI3) 10.66 (s, 1H), 8.43 (d, J = 9.0 Hz, 1H), 
7.42-7.23 (m, 7H), 6.22 (dd, J = 17.2,10.6 Hz, 1H), 5.55 (s, 2H), 5.12 (d, J = 10.6 Hz, 1H), 5.01 (d, J 
~ 17.2 Hz, 1H), 4.58 (s, 2H), 1.73 (s, 6H); 13C NMR (100 MHz, CDCI3) 6 188.4,154.0,146.3,138.0,
136.3, 129.9, 128.7, 128.5, 128.4, 128.1, 124.7, 123.8, 123.7, 117.4, 112.9, 110.2, 73.5, 70.5,
42,0, 30.7. Exact mass calcd for C22H22CIN02Na{M+Nar, 390.1231. Found 390.1232.
Ph Ph
MeONaOMe
CHO
MeOH,
Cl
BOMBOM dr 1:2BOM
Cycloadduct 3a, 3b. To diketopiperazine 5 (0.3 mmol) in methanol (1.5 mL, degassed with 
nitrogen) at rt was added chloroindole 4 (0.4 mmol) and a freshly prepared solution of sodium 
methoxide (1 mmol, 0.5 mL, 2.0 M). The reaction mixture was heated to 65 °C for 22 h. After 
cooling to rt, the reaction mixture was diluted with sat. aqueous NH4CI (10 mL) and extracted 
with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (10 mL), dried
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(Na2S04), filtered and concentrated in vacuo. The unpurified product was a 2:1 ratio of 
diastereomers as judged by 1H NMR spectroscopy. The product was purified by flash 
chromatography on silica gel (elution: 0% to 45% EtOAc in hexanes) to afford products 3a and 
3b (combined 255.1 mg, 85% yield) as a yellow oil: TLC (20% EtOAc in hexane) Rf -  0.20 (CAM);
[a]D25 = -8.8° (c = 0.77, CHCI3); IR (film) 1698, 1644, 1475, 1411, 1361, 1311, 1261, 1203, 1066,
885 cm-1; *H NMR (400MHz, CDCI3) 7.44 (d, J = 8.2 Hz, 0.5H), 7.40 (d, J = 8.2 Hz, 1H), 7.39-7.30 
(m, 20H), 7.26-7.23 (m, 2H), 7.19 (d, J = 1.6 Hz, 1H), 7.17 (d, J = 1.8 Hz, 2H), 7.10 (dd, J = 8.2,1.6 
Hz, 2H), 7.06 (dd, J = 8.4, 1.6 Hz, 1H), 6.27 (s, 0.5H), 6.19 (s, 1H), 5.66-5.47 (m, 4H), 4.63-4.48 
(m, 6.5H), 4.13 (d, J = 9.4 Hz, 0.5H), 4.12 (d, J = 9.8 Hz, 1H), 3.98 (d, J = 16.4 Hz, 1H), 3.86 (s, 3H),
3.76 (s, 1.5H), 3.28 (d, J = 17.2 Hz, 0.5H), 3.14 (d, J = 16.4 Hz, 1H), 2.54 (dd, J = 10.0, 3.7 Hz,
0.5H), 2.45 (dd, J = 10.0, 5.3 Hz, 1H), 2.38 (dd, J = 13.1, 10.0 Hz, 1H), 2.21 (dd, J = 13.1, 5.3 Hz,
1H), 2.17 (s,lH), 2.07 (dd, J = 12.9,10.2 Hz, 1H), 1.96 (dd, J = 12.9, 3.9 Hz, 1H), 1.59 (s, 1H), 1.48 
(s, 3H), 1.44 (s, 1.5H), 1.32 (s, 3H), 1.27 (s, 1.5 H); 13C NMR (100 MHz, CDCI3) 6 171.4, 169.0,
129.2, 129.1, 128.5, 128.5, 128.5, 128.3, 128.0, 128.0, 128.0, 128.0, 126.4, 126.4, 125.6, 120.5,
120.4, 119.5, 119.5, 109.3, 88.7, 88.5, 73.1, 69.8, 67.6, 67.5, 66.8, 63.4, 63.2, 54.7, 54.4, 48.6,
36.8, 31.0, 28.1, 27.8, 27.6, 25.7, 23.8, 21.5; Exact mass calcd for QsH^ClN^Na [M+Na]+, 
618.2130. Found 618.2126.
Ph Ph Ph
O
3b
MeO H O
+
ClCl 6bCl
BOM BOM BOMdr 1:2
Diketopiperazine 6b. To a solution of compounds 3a and 3b (200 mg, 0.34 mmol) in CH2CI2 
(33.5 mL) was added TsOH H20  (70 mg, 0.37 mmol) at 0°C. The reaction mixture was stirred at
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0°C for 1.5 h, and then sat. aqueous NaHC03 (2 mL) was added. The aqueous layer was 
separated and extracted with EtOAc (4 x 10 mL). The unpurified product was a 1:2 ratio of 
diastereomers as judged by NMR spectroscopy. The unpurified residue (223.7 mg) was 
dissolved in toluene (30 mL) and heated to 110°C. After 19 h, heat was removed, and the 
solution was concentrated in vacuo. The residue was purified by recrystallization from 25% 
EtOAc in hexane to afford product 6b (127 mg, 65% yield) as a colorless amorphous solid: TLC 
(40% EtOAc in hexane) R/0.20 (CAM); [a]D25= -2.7 (c 0.48, MeOH); IR (KBr pellet) 1721, 1690, 
1495, 1474, 1453, 1406, 1370, 1311, 1241, 1204, 1109, 1071, 929, 914, 881 cm'1; 2H NMR (400 
MHz, CDCI3) 7.38-7.31 (m, 11H), 7.18 (d, J = 1.6 Hz, 1H), 7.08 (dd, J = 8.2, 2.0 Hz, 1H), 6.42 (s, 
1H), 6.22 (s, 1H), 5.55 (d, J = 10.9 Hz, 1H), 5.52 (d, J = 11.3 Hz, 1H), 4.77 (d, J = 9.4 Hz, 1H), 4.58 
(d, J = 11.7 Hz, 1H), 4.51 (d, J = 11.7 Hz, 1H), 4.14 (d, J = 9.8 Hz, 1H), 3.78 (d, J = 15.6 Hz, 1H), 2.68 
(t, J = 7.4 Hz, 1H), 2.66 (d, J = 15.6 Hz, 1H), 2.34 (m, J = 7.8 Hz, 2H), 1.49 (s, 3H), 1.32 (s, 3H); 13C 
NMR (100 MHz, CDCI3) 6 171.5, 166.1, 140.5, 139.1, 136.3, 129.4, 128.6, 128.6, 128.2, 127.9,
126.5, 125.0, 120.8, 119.2, 109.6, 107.2, 89.3, 73.0, 70.0, 68.4, 65.1, 60.8, 50.6, 36.4, 29.9, 27.8,
25.0, 21.0; Exact mass calcd for C34H32CIN3 04Na [M + Na]+, 604.1973, found 604.1967.
Ph
H O
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Aldehyde 8. To a solution of compound 6b (63 mg, 0.11 mmol) in toluene (1 mL) at 0°C was 
added Dibal-H (2.10 mL, 1.0 M solution in toluene). The reaction was stirred for 0.5 h at 0°C, and 
then EtOAc (2 mL), potassium sodium tartrate tetrahydrate (100 mg), and water (2 mL) were 
successively added. The biphasic mixture was stirred rapidly for 1 h, and the organic layer was
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removed. The aqueous layer was extracted with additional EtOAc (3 x 10 mL). The organic layers 
were combined, dried (Na2S04), and concentrated in vacuo. The unpurified product was a single 
diastereomer as judged by 1H NMR spectroscopy. The residue was purified by flash 
chromatography on silica gel (elution: 45-65% EtOAc in hexane) to afford the derived 
intermediate aminoalcohol 7 (49 mg, 80% yield) as a yellow oil. Spectral data were in agreement 
with published data.9 To a portion of aminoalcohol 7 (43 mg, 0.08 mmol) in CH2CI2 (1.5 mL) at 
0°C was added DMSO (55 pL) and /Pr2NEt (100 pL, 0.57 mmol). To this solution was added 
S03pyridine (0.5 M, 450 pL). The solution was stirred for 30 min at 0°C and extracted with 
EtOAc (3 x 10 mL). The organic layers were combined, washed with brine, dried (Na2S04), and 
concentrated in vacuo. The residue was purified by flash chromatography on silica gel (elution: 
35-100% EtOAc in hexane) to afford product 8  (39 mg, 92% yield) as a yellow oil: TLC (50% 
EtOAc in hexane) R/0.25 (CAM); [a]D25= +20.9 (c 1.0, CH2CI2); IR (film) 1733, 1669, 1475, 1454, 
1360, 1318, 1266, 1240, 1202, 1132, 1065, 882, 805, 738 cm'1; *H NMR (400 MHz, CDCI3) 10.23 
(s, 1H), 7.43-7.18 (m, 11H), 7.06 (d, J = 8.2 Hz, 2H), 6.44 (s, 1H), 5.53 (s, 2H), 4.57 (s, 2H), 4.28 (d, 
J = 12.9 Hz, 1H), 3.31 (d, J = 12.9 Hz, 1H), 3.23 (d, J = 10.9 Hz, 1H), 2.88 (d, J = 15.6 Hz, 1H), 2.80 
(d, J = 15.2 Hz, 1H), 2.29-2.01 (m, 4H), 1.54 (s, 3H), 1.45 (s, 3H) 13C NMR (100 MHz, CDCI3) 6
198.9, 171.7, 141.2, 138.8, 137.7, 136.7, 128.6, 128.4, 128.4, 128.3 128.2, 127.9, 127.3, 125.0,
120.8, 118.8, 109.7, 106.6, 77.2, 73.0, 70.1, 66.5, 59.4, 59.2, 55.1, 47.3, 35.2, 30.1, 29.5, 28.8, 
22.5; Exact mass calcd for C34H34ClN30 3Na [M + Na]+, 590.2181, found 590.2184.
68
Me° N -
CHO 9 Me
0  ft
J l.P (O E t)2 Me
N-OMe
Cl
BOM
LiCI, /'Pr2NEt
MeCN Cl
O
BOM
Weinreb Amide 10. To a solution of compound 8 (39 mg, 0.069 mmol) in acetonitrile (3.8 mL) 
was added phosphonamide 9 (34 mg, 0.14 mmol), LiCI (23 mg, 0.54 mmol), and DBU (0.026 mL, 
0.17 mmol). The solution was stirred at rt for 1 h, and then H20 (2 mL) was added. The aqueous 
layer was separated and extracted with EtOAc (3 x 10 mL). The organic layers were combined, 
washed with brine, dried (Na2S04), and concentrated in vacuo. The residue was purified by flash 
chromatography on silica gel (elution: 60-80% EtOAc in hexane) to afford product 10 (27 mg, 
60% yield) as a yellow oil: TLC (60% EtOAc in hexane) R/  0.20 (CAM); [a] D25 = +8.9 (c = 0.09, 
CH2CI2); IR (film) 1682, 1629, 1472, 1455, 1418, 1374, 1313, 1241, 1204, 1131, 1061, 999, 882, 
800, 753 cm-1; XH NMR (400 MHz, CDCI3) 7.52-7.13 (m, 14H), 7.05 (dd, J = 8.4, 1.8 Hz, 1H), 6.33 
(s, 1H), 5.55 (s, 2H), 4.57 (d, J = 0.8 Hz, 2H), 4.28 (d, J = 13.7 Hz, 1H), 3.68 (s, 3H), 3.27 (s, 3H),
3.27 (d, J = 10.9 Hz, 1H), 3.13 (d, J = 13.3 Hz, 1H), 2.83 (q, J = 15.2 Hz, 2H), 2.30-2.25 (m, 2H), 
2.10-2.04 (m, 2H), 1.58 (s, 3H), 1.43 (s, 3H); 13C NMR (100 MHz, CDCI3) 6  172.0, 143.2, 141.5,
138.9, 138.5, 136.8, 128.6, 128.4, 128.3, 128.2, 128.1, 128.0, 127.0, 125.1, 122.0, 120.8, 118.7,
109.8,106.8, 73.1, 70.2, 62.0, 61.9, 60.1, 59.3, 54.9, 47.8, 35.1, 35.0, 30.3, 30.2, 22.5; Exact mass 
calcd for G ^ iC lN ^ N a  [M + Na]+, 675.2709, found 675.2702.
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Premalbrancheamide. To a solution of compound 10 (26 mg, 0.39 mmol) in PhMe (1 mL) at 
-78°C was added a solution of Dibal-H (1.0 M in PhMe, 0.20 mL). The solution was stirred for 1 
h, and then MeOH (1 mL), HCI (1 mL), EtOAc (1 mL), and potassium sodium tartrate*4H20 (50 
mg) was added. After an additional 1 h of stirring, the aqueous layer was separated and 
extracted with EtOAc (3 x 10 mL). The organic layers were combined, dried (Na2S04), and 
concentrated in vacuo. The residue was quickly purified by flash chromatography on silica gel 
(elution: 40-100% EtOAc in hexanes) to afford product 11 (15.5 mg, 67% yield) as a light yellow
oil. Aldehyde 11 was unstable and prone to decomposition; accordingly, the product was used 
immediately in the following reduction sequence. To a solution of compound 11 (7.0 mg, 0.015 
mmol) in MeOH (1.0 mL) was added Pd/C (17 mg) at rt. The solution was sparged with H2. After 
5 min, the H2 was stopped and Ar was bubbled through the solution. The suspension was 
filtered through Celite and concentrated in vacuo to afford a mixture containing predominantly 
premalbrancheamide (4.0 mg, 65% yield): TLC (80% EtOAc in hexane) R/  0.25 (CAM). Spectral 
data for premalbrancheamide were in agreement with published data.1011
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Methyl Ester 15. To a solution of compound 8 (110 mg, 0.19 mmol) in acetonitrile (10 mL) was 
added trimethyl phosphonoacetate 14 (0.065 mL, 0.40 mmol), LiCI (67 mg, 1.60 mmol), and DBU 
(0.075 mL, 0.50 mmol). The solution was stirred at rt for 1 h, and then H20  (2mL) was added. 
The aqueous layer was separated and extracted with EtOAc (3 x 10 mL). The organic layers were 
combined, washed with brine, dried (Na2S04), and concentrated in vacuo to give a 3:1 mixture of 
E and Z isomers of 15 as shown by 1H NMR spectroscopy. The residue was purified by flash 
chromatography on silica gel (elution: 40-100% EtOAc in hexane) to afford product 15 (110 mg, 
91% yield) as a yellow oil: TLC (40% EtOAc in hexane) R/0.40 (CAM); [a]D25= +7.9 (c 2.4, CH2CI2); 
IR (film) 1724, 1685, 1608, 1562, 1495, 1475, 1454, 1359, 1308, 1241, 1202, 1174, 1131, 1062, 
882, 803, 740 cm"1; NMR (400 MHz, CDCI3) 7.51 (d, J = 16.4 Hz, 1H), 7.38-7.18 (m, 12H), 7.05 
(d, J = 8.2, 1H), 6.63 (d, J = 16.4 Hz, 1H), 5.55 (s, 2H), 4.60-4.54 (m, 2H), 4.25 (d, J = 12.9 Hz, 1H), 
3.78 (s, 3H), 3.71 (s, 1H), 3.26 (d, J = 10.9 Hz, 1H), 3.13 (d, J = 13.3 Hz, 1H), 2.89-2.81 (m, 2H), 
2.25-2.05 (m, 4H), 1.58 (s, 3H), 1.43 (s, 3H); 13C NMR (100 MHz, CDCI3) 6 171.9, 166.8, 145.2,
141.3, 138.8, 138.3, 136.8, 128.6, 128.4, 128.3, 128.3, 128.2, 128.1, 128.0, 127.9, 127.1, 125.0,
124.1, 120.8, 120.7, 118.8, 109.7, 106.8, 77.2, 73.0, 70.1, 61.6, 59.8, 59.3, 54.9, 51.7, 47.8, 35.1,
34.6, 30.3, 30.0, 24.3, 22.4; Exact mass calcd for C37H38ClN30 4Na [M + Na]+, 646.2443, found 
646.2436.
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Saturated Alcohol 17. To a solution of compound 15 (36 mg, 0.059 mmol) in THF (1.0 mL) at 0°C 
was added NaBH4 (24 mg, 0.64 mmol) and Lil (76 mg, 0.57 mmol). The solution was warmed to 
rt, and additional NaBH4 and Lil (10 equivalents each) were added in three portions after 
successive 12 h increments. After 48 h, sat. aqueous NH4CI (1 mL) was added. The aqueous layer 
was separated and extracted with EtOAc (3 x 10 mL). The organic layers were combined, washed 
with brine, dried (Na2S04), and concentrated in vacuo to give a 1:3 mixture of alcohols 16 and 17 
as shown by *H NMR spectroscopy. The residue was purified by flash chromatography on silica 
gel (elution: 50-100% EtOAc in hexanes) to afford product 17 (20 mg, 58% yield) as a white 
solid: mp 92.7-94.2°C; TLC (60% EtOAc in hexane), R/0.15 (CAM); [a]D25 = +1.4 (c 0.85, CH2CI2); 
IR (film) 1740, 1672, 1473, 1453, 1359, 1318, 1240, 1205, 1059, 882, 802, 746 cm-1; *H NMR 
(400 MHz, CDCI3) 7.40-7.13 (m, 12H), 7.04 (d, J = 8.2 Hz, 1H), 6.56 (s, 1H), 5.54 (s, 2H), 4.56 (s, 
2H), 4.27 (d, J = 12.9 Hz, 1H), 3.78-3.72 (m, 2H), 3.11 (d, J = 10.9 Hz, 1H), 3.06 (d, J = 12.5 Hz, 
1H), 2.81 (d, J = 15.6, 1H), 2.76 (d, J = 15.2, 1H), 2.48 (s, 1H), 2.27 (dd, h  = 13.3, J2 = 4.3 Hz, 1H), 
2.20 (d, J = 11.3 Hz, 1H), 2.07-1.98 (m, 2H), 1.93 (d, J = 11.7, 2H), 1.88-1.83 (m, 2H), 1.52 (s, 3H), 
1.44 (s, 3H); 13C NMR (100 MHz, CDCI3) 6 174.4, 141.6, 138.8, 138.5, 136.8, 128.6, 128.4, 128.3, 
128.2, 127.9, 127.0, 125.1, 120.8, 118.7, 109.7, 106.8, 77.2, 73.1, 70.1, 62.7, 60.2, 59.6, 57.3,
54.5, 47.3, 35.1, 30.4, 30.2, 30.1, 26.9, 26.4, 22.3; Exact mass calcd for C36H4oCIN303  Na [M + 
Na]+, 620.2650, found 620.2643. Alcohol 17 can also be prepared from 16 as follows. To a 
solution of compound 16 (6.0 mg, 0.0092 mmol) in EtOH (0.4 mL) at rt was added 4- 
methylbenzene sulfonhydrazide (2 mg, 0.010 mmol) and NaOAc (lmg, 0.010 mmol). The
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solution was heated to reflux, and additional portions (0.010 mmol) of sulfonhydrazide and 
NaOAc were added after 2 h. After 6.5 h at reflux, heat was removed, and the solution was 
concentrated in vacuo. Sat. aqueous Na2C03 (2 mL) and EtOAc (2 mL) were added to the residue, 
and the aqueous layer was separated and extracted with additional EtOAc ( 3 x 5  mL). The 
organic layers were combined, washed with brine, dried (Na2S04), and concentrated in vacuo. 
The residue was purified by flash chromatography according to the above procedure to afford 
17 (3.3 mg, 60% yield) as a white solid.
1. i. MsCI, pyr 
ii. PhMe 120°C
2. Kl, NEt3, PhMe, 120°C 
3. i. TsOH H20; 
ii. NaH0O3; PhMe, A
(+)-1
H O
Cl
Malbrancheamide B (1). To a solution of compound 17 (24 mg, 0.040 mmol) in CH2CI2 (0.4 mL) 
at 0°C was added pyridine (6.3 pL, 0.079 mmol) and MsCI (3.4 pL, 0.043 mmol). The solution was 
allowed to warm to rt with stirring, and additional portions of MsCI (3.4 pL, 0.043 mmol) were 
added every 3 h. After a total of 12 h, sat. aq. NaHC03 (2 mL) was added. The aqueous layer was 
separated and extracted with EtOAc (3 x 10 mL). The organic layers were combined, washed 
with brine, dried (Na2S04), and concentrated in vacuo. The resulting residue (22 mg) was 
dissolved in toluene (2 mL) and heated to 125°C in a sealed tube with stirring. After 10 h, heat 
was removed, and the solution was concentrated in vacuo. To a solution of the unpurified 
residue (18 mg) in toluene (1.5 mL) was added Kl (6.0 mg, 0.035 mmol) and NEt3 (0.15 mL) in a 
sealed tube. The solution was heated to 125°C and stirred for 20 h. After 20 h, heat was 
removed, and the solution was concentrated in vacuo. To a solution of the unpurified residue 
(13 mg) in CH2CI2 (2.6 mL) was added TsOHH20 (15.8 mg, 0.083 mmol) at 0°C. The solution was 
allowed to warm to rt with stirring, and an additional portion of TsOH H20 (14 mg, 0.072 mmol)
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was added after 2 h. After a total of 4 h, NaHC03 (2 mL) was added. The aqueous layer was 
separated and extracted with EtOAc (4 x 10 mL). The organic layers were combined, washed 
with brine, dried (Na2S04), and concentrated in vacuo. The product was purified by flash 
chromatography on silica gel (elution: 0-10% MeOH in CHCI3) to afford product 1 (6.0 mg, 40% 
yield) as an amorphous colorless solid: TLC (5% MeOH in CHCI3), R/0.50 (CAM); [cx]D25 = +25 (c
0.4, MeOH), Lit.12 [a]D = +50 (c 1, MeOH), Lit.613 (-)-l, [a]D = -36 (c 0.81, MeOH), Lit.14 [a]D = +28 
(c 0.5, MeOH); HPLC trace and UV signature identical for both synthetic and an authentic natural 
sample of 1; Mobile phase, gradient mixture of H20 + 0.1% TFA/MeCN, 1.0 mL/min; 0-10 min 
20% MeCN, 10.01-20 min 20-50% MeCN); Phenomenex C18 Luna (250 mm x 4.6 mm x 5 |im), 
retention time 15.17 min; UVX 230, 283 nm; IR (film) 1653,1465,1361,1319,1291,1253,1227, 
1198,1131,1099,1059,1024, 904, 797 cm"1; Exact mass calcd for C2iH24CIN30[M+H]+, 370.1681, 
found 370.1677. JH and 13C NMR spectral data for synthetic material both match the data for 
the authentic sample and are in agreement with published data.15a,6,12b
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Cycloadducts 21a, 21b, 21c. To diketopiperazine 20 (18 mg, 0.11 mmol) in MeOH (0.1 mL, 
degassed with nitrogen) at rt in a sealed tube was added 4 (20 mg, 0.05 mmol) and a freshly 
prepared solution of NaOMe in MeOH (5 equiv, 0.3 mL, 5.0 M). The reaction vessel was heated 
to 90°C (bath temperature) for 68 h. After cooling to rt, the reaction mixture was diluted with 
sat. aqueous NH4CI (1 mL) and extracted with EtOAc ( 4 x 5  mL). The combined organic layers 
were washed with brine (5 mL), dried (Na2S04), filtered and concentrated in vacuo to give a
1.7:1.0:2.9 mixture of cycloadducts 21a, 21b, and 21c as determined by JH NMR spectroscopy 
on the unpurified mixture of products. The residue was purified by flash chromatography on 
silica gel (elution: 0-5% MeOH in CHCI3) to afford products 21a (8.0 mg, 29% yield), 21b (6.0 mg, 
22% yield), and 21c (13.0 mg, 48% yield).
21a: (light yellow oil) TLC (5% MeOH in CHCI3), R/0.55 (CAM); IR (film) 1685, 1633, 1476, 1419, 
1354, 1324, 1260, 1205, 1179, 1092, 1077, 1055, 1001, 920, 886, 838, 799, 740, 702 cm-1; *H 
NMR (400 MHz, CDCI3) 7.50 (d, J = 8.2 Hz, 1H), 7.38-7.30 (m, 5H), 7.19 (s, 1H), 7.10 (dd, J = 8.2,
1.6 Hz, 1H), 5.59 (d, J = 11.3 Hz, 1H), 5.53 (d, J = 11.3 Hz, 1H), 4.56 (d, J = 11.7 Hz, 1H), 4.50 (d, J =
75
11.7 Hz, 1H), 3.91 (d, J = 17.6 Hz, 1H), 3.71 (s, 3H), 3.54-3.43 (m, 2H), 3.28 (d, J = 17.2 Hz, 1H), 
2.71-2.64 (m, 1H), 2.41 (dd, J = 9.6, 4.1 Hz, 1H), 2.09-1.84 (m, 5H), 1.39 (s, 3H), 1.23 (s, 3H); 13C 
NMR (100 MHz, CDCI3) 6 172.2, 170.9, 141.3, 139.3, 137.3, 128.8, 128.2, 128.1, 126.4, 120.6, 
120.0, 109.5, 109.4, 73.3, 70.0, 66.8, 64.4, 54.6, 47.6, 43.8, 36.9, 34.5, 29.3, 27.9, 26.4, 24.9, 
24.1; Exact mass calcd for C3oH32CIN303Na [M + Na]+, 540.2024, found 540.2017.
21b: (light yellow oil) TLC (5% MeOH in CHCI3), R/0.52 (CAM); IR (film) 1678, 1638, 1475, 1419, 
1356,1310, 1265,1200, 1060, 882, 800, 736, 699 cm-1; *H NMR (400 MHz, CDCI3) 7.46 (d, J = 8.2 
Hz, 1H), 7.39-7.30 (m, 5H), 7.18 (d, J = 1.6 Hz, 1H), 7.09 (dd, J = 8.2, 2.0 Hz, 1H), 5.55 (d, J = 5.1 
Hz, 2H), 4.56 (d, J = 12.1 Hz, 1H), 4.48 (d, J = 12.1 Hz, 1H), 3.99 (d, J = 16.4 Hz, 1H), 3.80 (s, 3H), 
3.51-3.33 (m, 2H), 3.08 (d, J = 16.4 Hz, 1H), 2.68-2.66 (m, 1H), 2.34 (dd, J = 10.4, 5.1 Hz, 1H), 
2.04-1.92 (m, 4H), 1.83 (dd, J = 12.9, 5.1 Hz, 1H), 1.42 (s, 3H), 1.18 (s, 3H); 13C NMR (100 MHz, 
CDCI3) 6 172.9,171.3,140.7, 139.1,137.1,128.5, 128.0, 127.9,125.7, 120.4, 119.6,109.9,109.2,
73.1, 69.7, 65.5, 64.3, 54.5, 54.5, 48.8, 43.4, 36.7, 32.8, 29.3, 27.8, 24.8, 21.4; Exact mass calcd 
for C3oH32CIN303Na [M + Na]+, 540.2024, found 540.2017.
21c: (colorless solid) mp 224.2-225.6°C; TLC (5% MeOH in CHCI3), R/0.50 (CAM); IR (KBr pellet) 
3199, 1691, 1475, 1455, 1199, 1098, 1058, 883, 811, 733, 697 cm-1; *H NMR (400 MHz, DMSO) 
8.76 (s, 1H), 7.57 (s, 1H), 7.44 (d, J = 8.6 Hz, 1H), 7.37-7.28 (m, 5H), 7.10 (dd, J = 8.6, 2.0 Hz, 1H), 
5.69 (d, J = 10.9 Hz, 1H), 5.64 (d, J = 10.9 Hz, 1H), 4.59 (s, 2H), 3.44 (d, J = 15.6 Hz, 1H), 3.35 (s, 
1H), 3.33-3.23 (m, 1H), 2.72 (d, J = 16.0 Hz, 1H), 2.55-2.50 (m, 2H), 2.12-1.81 (m, 5H), 1.36 (s, 
3H), 1.09 (s, 3H); 13C NMR (100 MHz, DMSO) 6 173.0, 168.2, 141.5, 138.6, 137.5, 128.3, 127.7, 
127.7, 126.8, 125.0, 120.0, 119.1, 109.8, 107.2, 73.1, 69.0, 66.1, 58.9, 50.2, 43.6, 35.8, 30.5,
28.6, 27.1, 24.0, 23.6, 20.3; Exact mass calcd for C29H3oCIN303Na [M + Na]+, 526.1868, found 
526.1862.
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Oxomalbrancheamide B (22). To a solution of compound 21b (6 mg, 0.012 mmol) in CH2CI2 (0.5 
mL) at 0°C was added TsOHH20 (6 mg, 0.029 mmol). The solution was allowed to warm to rt 
with stirring, and an additional portion of TsOH H20 (6 mg, 0.029 mmol) was added after 2 h. 
After a total of 4 h, sat. aqueous NaHC03 (2 mL) was added. The aqueous layer was separated 
and extracted with EtOAc (4 x 10 mL). The organic layers were combined, washed with brine, 
dried (Na2S04), and concentrated in vacuo. The unpurified residue (4 mg) was dissolved in 
toluene (1 mL) and heated to 125°C in a sealed tube with stirring. After 22 h, heat was removed, 
and the solution was concentrated in vacuo. The residue was purified by flash chromatography 
on silica gel (elution: 5% MeOH in CHCI3) to afford product 22 (3.0 mg, 61% yield). 22 was also 
prepared from 21c as follows: to a solution of compound 21c (11 mg, 0.021 mmol) in CH2CI2(0.5 
mL) at 0°C was added TsOH H20 (10 mg, 0.053 mmol). The solution was allowed to warm to rt 
with stirring, and an additional portion of TsOH-H20 (10 mg, 0.053 mmol) was added after 2 h. 
After a total of 4 h, sat. aqueous NaHC03 (2 mL) was added. The aqueous layer was separated 
and extracted with EtOAc (4 x 10 mL). The organic layers were combined, washed with brine, 
dried (Na2S04), and concentrated in vacuo. The unpurified residue (12.4 mg) was dissolved in 
toluene (1 mL) and heated to 125°C in a sealed tube with stirring. After 17 h, heat was removed, 
and the solution was concentrated in vacuo. The residue was purified by flash chromatography 
on silica gel (elution: 5% MeOH in CHCI3) to afford product 22 (7.0 mg, 87% yield). Spectral data 
were in agreement with published data.153
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APPENDIX 
SUPPORTING INFORMATION FOR:
CHAPTER II:
General Information. All reactions were carried out under an atmosphere of nitrogen in flame- 
dried or oven-dried glassware with magnetic stirring unless otherwise indicated. Acetonitrile, 
THF, toluene, and Et20  were degassed with argon and purified by passage through a column of 
molecular sieves and a bed of activated alumina.1 Dichloromethane was distilled from CaH2 prior 
to use. All reagents were used as received unless otherwise noted. Flash column 
chromatography2 was performed using SiliCycle siliaflash P60 silica gel (230-400 mesh). 
Analytical thin layer chromatography was performed on SiliCycle 60A glass plates. Visualization 
was accomplished with UV light, anisaldehyde, eerie ammonium molybdate, potassium 
permanganate, or ninhydrin, followed by heating. Film (or KBr pellet) infrared spectra were 
recorded using a Digilab FTS 7000 FTIR spectrophotometer. Optical rotations were determined 
on either a Perkin-Elmer 341 polarimeter at 25 °C. JH NMR spectra were recorded on a Varian 
Mercury 400 (400 MHz) spectrometer and are reported in ppm using solvent as an internal 
standard (CDCI3 at 7.26 ppm) or tetramethylsilane (0.00 ppm). Proton-decoupled 13CNMR 
spectra were recorded on a Mercury 400 (100 MHz) spectrometer and are reported in ppm 
using solvent as an internal standard (CDCI3 at 77.00 ppm). All compounds were judged to be 
homogeneous (>95% purity) by JH and 13C NMR spectroscopy. Mass spectra data analysis was 
obtained through positive electrospray ionization (w/ NaCI) on a Bruker 12 Tesla APEX-Qe 
FTICR-MS with an Apollo II ion source. HPLC was performed on a Shimadzu Prominence with 
LC20AT pumps and photodiode array detector.
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SUPPORTING INFORMATION FOR:
CHAPTER III:
General Information. All reactions were carried out under an atmosphere of nitrogen in flame- 
dried or oven-dried glassware with magnetic stirring unless otherwise indicated. Acetonitrile, 
THF, toluene, and Et20  were degassed with argon and purified by passage through a column of 
molecular sieves and a bed of activated alumina.1 Dichloromethane was distilled from CaH2 prior 
to use. All reagents were used as received unless otherwise noted. Flash column 
chromatography2 was performed using SiliCycle siliaflash P60 silica gel (230-400 mesh). 
Analytical thin layer chromatography was performed on SiliCycle 60A glass plates. Visualization 
was accomplished with UV light, anisaldehyde, eerie ammonium molybdate, potassium 
permanganate, or ninhydrin, followed by heating. Film (or KBr pellet) infrared spectra were 
recorded using a Digilab FTS 7000 FTIR spectrophotometer. Optical rotations were determined 
on either a Perkin-Elmer 341 polarimeter at 25 °C. XH NMR spectra were recorded on a Varian 
Mercury 400 (400 MHz) spectrometer and are reported in ppm using solvent as an internal 
standard (CDCI3 at 7.26 ppm) or tetramethylsilane (0.00 ppm). Proton-decoupled 13CNMR 
spectra were recorded on a Mercury 400 (100 MHz) spectrometer and are reported in ppm 
using solvent as an internal standard (CDCI3 at 77.00 ppm). All compounds were judged to be 
homogeneous (>95% purity) by aH and 13C NMR spectroscopy. Mass spectra data analysis was 
obtained through positive electrospray ionization (w/ NaCI) on a Bruker 12 Tesla APEX-Qe 
FTICR-MS with an Apollo II ion source. HPLC was performed on a Shimadzu Prominence with 
LC20AT pumps and photodiode array detector.
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